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ABSTRACT 
Despite latest advances on antiretroviral therapeutics, HIV infection continues to 
be a chronic condition with serious complications and burden costs of treatment. The 
rapidly emergence of resistant strains constitutes a major contributor for failure of 
standard therapy. Accordingly, there is a continuous need for design of innovative HIV 
inhibitors against conserved and important targets on virus replication cycle. On the other 
hand, the exploration of novel classes of HIV inhibitors results in a necessity for novel 
efficient and specific delivery systems.   
In the present thesis, we manage to target HIV infection through two distinct 
therapeutic approaches based on single-domain antibody (sdAb) technology. In the first 
one, we developed a novel fusion inhibitor of HIV by rationally engineering the binding 
sites of a stable light-chain scaffold from rabbit-origin. From five sdAbs with specificity 
to the conserved and crucial-to-fusion N36 viral sequence, one potently inhibited HIV-1 
infectivity. The selected fusion inhibitor, named F63, was capable of broadly inhibiting 
distinct strains of HIV-1 with an antiviral potency similar to the T-20 entry inhibitor, 
clinically approved for HIV/AIDS treatment. Moreover, F63 presented an effective 
neutralization activity against HIV type 2, which constitutes an advantage relative to the 
limited antiviral breadth of T-20. In the second approach, we took advantage of a 
previously validated variable domain from camel (nanobody) to design a strategy for 
CXCR4-targeted delivery of HIV expression inhibitors. The engineered nanobody-based 
vehicle delivered an anti-HIV small interfering RNA specifically to CXCR4-bearing 
cells—susceptible to HIV infection—being the activity of the delivered RNAi effector 
proved by virus promoter silencing and inhibition of HIV replication. A second version 
of this construct allowed to deliver a zinc-finger transcription factor, which functionality 
depends on CXCR4-mediated endocytosis as mechanism of cellular crossing-over.  
In resume, this study demonstrates the potential of engineering single-domain 
antibodies for HIV therapeutics and gives insights into the design of novel antiviral drugs. 
Keywords: Single-domain antibody; HIV, Fusion inhibitor; Targeted delivery; 
Nanobody. 
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RESUMO 
O Síndrome da Imunodeficiência Adquirida (SIDA) apresenta-se como um dos 
principais problemas de Saúde Pública a nível mundial, tendo sido responsável por 
milhões de vítimas desde a sua descoberta. Esta doença é caracterizada por uma grave 
deterioração do sistema imunológico dos indivíduos afetados, o que resulta no 
aparecimento de infeções oportunistas fatais. A SIDA foi pela primeira vez descrita em 
1981, em consequência da deteção em indivíduos jovens de doenças resultantes de uma 
imunodeficiência demarcada. Estes acontecimentos culminaram no isolamento dos 
agentes etiológicos da doença, o Vírus da Imunodeficiência Humana tipo 1 e tipo 2 (HIV-
1 e HIV-2 do inglês Human Immunodeficiency Virus). A síndrome causada pelo HIV-1 é 
mais severa e a taxa de transmissão apresentada por este tipo de vírus mais elevada. 
Devido a estas características, o HIV-1 constitui um alvo terapêutico preferencial 
relativamente ao HIV tipo 2. Apesar dos desenvolvimentos recentes na terapia 
antirretroviral, uma estratégia eficaz contra a infeção por HIV continua a estar 
indisponível, sendo o contínuo aparecimento de estirpes resistentes um dos principais 
obstáculos para a erradicação desta doença. Como tal, o desenvolvimento de novas 
estratégias terapêuticas assim como de métodos para a sua entrega eficiente continua a 
constituir uma necessidade urgente na terapia desta grave doença. 
A engenharia de anticorpos surge como uma ferramenta importante para o 
desenvolvimento de novas terapias biológicas. Esta abordagem é particularmente 
importante no contexto da infeção por HIV devido à dificuldade em isolar anticorpos 
neutralizantes e com largo espectro de ação a partir de indivíduos infetados. Este facto 
prende-se com os diversos mecanismos de evasão imunológica apresentados pela 
glicoproteína viral de superfície responsável pelo processo de entrada do vírus infecioso 
na célula hospedeira. Entre estes destaca-se a localização de difícil acesso de 
sequências/regiões virais conservadas e críticas para o ciclo replicativo do vírus, que 
impossibilita o seu reconhecimento por anticorpos de tamanho tradicional. Neste 
contexto, a redução do tamanho do anticorpo para formatos pequenos, como os anticorpos 
de domínio único, constitui uma vantagem tremenda na ligação a estes epítopos. Os 
anticorpos de domínio único são apenas constituídos pelo domínio variável da cadeia leve 
ou pesada de um anticorpo. Estes fragmentos podem ser obtidos a partir de outros 
formatos de anticorpos ou selecionados a partir de bibliotecas. De entre estas, as 
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bibliotecas sintéticas são as que permitem maior controlo sobre a sua representatividade, 
visto que a sua diversidade pode ser cuidadosamente estudada e inserida por engenharia 
genética. Por outro lado, certos anticorpos de tamanho único, como os “nanobodies”, 
permitem o uso de alvos celulares com objetivos terapêuticos devido não só ao seu 
tamanho reduzido, mas a propriedades favoráveis de ligação. Adicionalmente, estes 
fragmentos de anticorpos possuem extraordinárias características biofísicas que os 
tornam atrativos para diversas aplicações, nomeadamente engenharia genética para fins 
terapêuticos. Estes formatos em particular permitem a exploração de novas abordagens 
em medicina, como a entrega específica de moléculas terapêuticas.  
A glicoproteína Env é responsável por mediar o processo de fusão entre o vírus 
de HIV e a célula hospedeira, apresentando-se como um alvo terapêutico atrativo devido 
à sua acessibilidade na superfície da partícula viral e papel fundamental no processo de 
entrada. Como tal, o Capítulo II desta dissertação de doutoramento teve como objetivo 
desenvolver um novo inibidor de fusão da infeção por HIV através da ligação de um 
anticorpo de domínio único a uma zona conservada e crítica da glicoproteína Env—região 
N36. Para tal e baseados numa estratégia racional de desenho, construímos uma biblioteca 
sintética de anticorpos de domínio único usando um fragmento variável de coelho como 
base. As regiões de ligação ao antigénio deste fragmento foram ampliadas e modificadas 
de modo a tornarem-se mais flexíveis e aptas para ligar à zona extremamente côncava 
onde a sequência N36 se situa. A partir da biblioteca sintética foram selecionados, pela 
tecnologia de “phage display”, cinco fragmentos de anticorpos distintos que apresentaram 
ligação específica ao péptido N36 e impediram a infeção pela estirpe laboratorial HIV-1 
NL4-3. Um destes fragmentos, F63, apresentou uma capacidade de neutralização potente 
e abrangente de diversas estirpes virais primárias quer de HIV-1 como de HIV-2, em 
alguns casos superior ao único inibidor de fusão aprovado no mercado, T-20. Este facto 
poderá em parte ser explicado pelo epítopo do fragmento F63 apenas parcialmente se 
sobrepor à região de ligação do péptido T-20. O anticorpo de domínio único F63 
apresentou ainda uma ligação específica a membranas lipídicas, uma propriedade 
previamente associada a outros potentes inibidores de entrada.   
A exploração de novas classes de inibidores antirretrovirais resulta numa 
necessidade crescente de desenvolver plataformas e estratégias para a sua entrega 
específica. Como tal, o Capítulo III da presente dissertação de doutoramento teve como 
objetivo a entrega específica de inibidores da expressão viral a células suscetíveis à 
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infeção por HIV. Para tal, tomámos partido de um domínio variável de camelo 
(“nanobody”) previamente validado para o co-recetor de HIV-1 CXCR4 e construímos 
uma quimera como veículo de entrega de uma pequena molécula terapêutica de RNA de 
interferência (siRNA do inglês small interfering RNA). Os “nanobodies” são domínios 
variáveis autónomos derivados de um tipo peculiar de anticorpos apenas constituídos por 
cadeias pesadas, existentes em alguns membros da família Camelidae. Estes formatos 
naturalmente apresentam características biofísicas favoráveis e aptidão para 
reconhecerem epítopos não-convencionais. A quimera aqui desenvolvida foi capaz de 
entregar especificamente o efetor de RNA de interferência a células contendo o recetor 
CXCR4 na sua superfície. A funcionalidade da molécula de RNA entregue por endocitose 
foi também comprovada pelo silenciamento do promotor de HIV e da inibição da 
replicação viral em células portadoras do mesmo recetor. Adicionalmente, os resultados 
deste capítulo revelaram a aplicação deste “nanobody” numa estratégia de funcionalidade 
dependente da via de entrega. Nesta abordagem alternativa, um fator de transcrição 
constituído por uma proteína dedos-de-zinco foi conjugado com dois “nanobodies”, um 
que reconhece o recetor CXCR4 e outro irrelevante. Alguns destes fatores de transcrição 
artificiais baseados na tecnologia de proteínas dedos-de-zinco possuem a capacidade inata 
de transpor a membrana celular e ganhar acesso ao meio intracelular, não necessitando 
de um método de translocação. No entanto, esta via de entrada é inespecífica, levando a 
um processo de distribuição ineficiente e em alguns casos indesejado. Os resultados deste 
estudo indicam que das duas quimeras apenas o fator de transcrição entregue por 
endocitose através do recetor CXCR4, em vez da via normal não específica de entrada 
destes fatores, funcionou como repressor da expressão do genoma do HIV a partir do 
promotor viral.  
Em resumo, os resultados obtidos nesta dissertação de doutoramento demonstram 
o potencial dos anticorpos de domínio único como agentes de terapia da infeção por HIV, 
quer através da sua atividade neutralizante como inibidores de fusão ou na entrega de 
novas classes de moléculas terapêuticas. Adicionalmente, esta dissertação fornece 
informação relevante sobre novos alvos terapêuticos e a construção de potentes e 
promissores inibidores antirretrovirais.   
 
Palavras-chave: Anticorpo de domínio único, HIV, Inibidor de fusão, Entrega específica, 
“Nanobody”
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ABBREVIATIONS 
Aa Amino acid   
AAV Adeno-associated virus   
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AIDS Acquired Immunodeficiency Syndrome   
APC Allophycocyanin   
ATF Artificial transcription factor   
aTTP Acquired thrombotic thrombocytopenic purpura   
BCR B-cell receptor   
bNAb Broadly neutralizing antibody   
BSA Bovine serum albumin   
CA Capsid   
CAR Chimeric antigen receptor   
cART Combination antiretroviral therapy   
CCR5 CC-chemokine receptor 5   
CD4 Cluster of differentiation 4   
CD4bs CD4 binding-site   
CDR Complementary determining region   
CDR1 Complementary determining region 1   
CDR2 Complementary determining region 2   
CDR3 Complementary determining region 3   
CH Heavy-chain constant domain   
Chol Cholesterol   
CL Light-chai constant domain   
CRF Circulating recombinant form   
CRISPR/Cas9 Clustered regularly-interspaced short palindromic 
repeats/CRISPR-associated protein 9  
  
CXCR4 CXC-chemokine receptor 4   
CTD C-terminal repeat domain   
C3PO Component 3 promoter of RISC   
DART Dual-affinity re-targeting   
dsRNA Double-stranded RNA   
DVN Degenerate codon   
d1EGFP Destabilized variant 1 of EGFP reporter   
EC50 50% effective concentration   
E. coli Escherichia coli   
e-gp41 Gp41 ectodomain   
Env Envelope glycoprotein   
ER Endoplasmatic reticulum   
ESCRT Endosomal sorting complexes required for transport   
Fab Fragment antigen-binding   
FBS Fetal bovine serum   
Fc Fragment crystallizable   
FDA USA Food and Drug Administration   
FITC Fluorescein   
FP Fusion peptide   
Gag Group-specific antigen   
H Heavy-chain   
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HA Hemagglutinin A   
HCAb Heavy-chain only antibody   
HEL Hen egg-white lysozyme   
HIV Human Immunodeficiency Virus   
HIV-1 Human Immunodeficiency Virus type 1   
HIV-1NL4-3 HIV-1 laboratory-adapted strain NL4-3   
HIV-2 Human Immunodeficiency Virus type 2   
HR1 Heptad repeat 1   
HR2 Heptad repeat 2   
IC50 50% inhibitory concentration   
Ig Immunoglobulin   
IgA Immunoglobin class A   
IgD Immunoglobin class D   
IgE Immunoglobin class E   
IgG Immunoglobin class G   
IgM Immunoglobin class M   
IMAC Immobilized metal ion affinity chromatography   
IN Integrase   
INSTI Integrase inhibitor   
IPTG Isopropyl β-D-1-thiogalactopyranoside   
IU Infectious unit   
Ka Association rate   
Kd Dissociation rate   
KD Affinity constant   
KRAB Krüppel-associated box   
LB Lysogeny broth   
LTR Long terminal repeat   
LUV Large unilamellar vesicles   
MA Matrix   
mAb Monoclonal antibody   
MFI Mean Fluorescence Intensity   
miRNA Micro RNA   
MLV Multilamellar vesicle   
MPER Membrane proximal external region   
MVC Maraviroc   
MW Molecular weight   
n.a. Not applicable   
Nb Nanobody   
NC Nucleocapsid   
NF-kB Factor nuclear kappa B   
NLS Nucleolar localization signals   
NRTI Nucleoside/nucleotide reverse transcriptase inhibitor   
nNRTI Non-nucleoside reverse transcriptase inhibitor   
ORF Open reading frame   
PBS tRNA primer-binding site   
PBMCs Peripheral blood mononuclear cells   
PI Protease inhibitor   
Pol Polymerase   
Pol II RNA polymerase II   
 xi 
 
POPC 1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine   
Pre-miRNA Precursor miRNA   
Pri-miRNA Primary miRNA   
PR Protease   
PrEP Pre-exposition prophylaxis   
P-TEFb Transcription elongation factor b   
RISC RNA-induced silencing complex   
RNAi RNA interference   
RT Reverse transcriptase   
SB Super broth   
scFv Single-chain variable fragment   
SD Standard deviation   
sdAb Single-domain antibody   
SDF-1α Stromal cell-derived factor 1-alpha   
SEM Standard error of the mean    
SHIV HIV/SIV chimera   
shRNA Short-hairpin RNA   
siRNA Small interfering RNA   
SMIP Small modular immunopharmaceutical   
SNALP Stable nucleic acid lipid particle   
SP1 Specificity protein 1   
SPR Surface plasmon resonance   
Tat Trans-activator of transcription   
TAR Trans-activating response element   
TBP TATA binding protein   
TCID50 50% tissue culture infectious dose   
UNAIDS The Joint United Nations Programme on HIV/AIDS   
VH Heavy-chain variable domain   
VL Light-chain variable domain   
VP16 Viral protein 16   
VS Virological synapse   
ZF-TF Zinc-finger transcription factor   
ZFP Zinc-finger protein   
6HB Six-helical bundle   
 
Amino acids 
A Alanine L Leucine 
R Arginine K Lysine 
N Asparagine M Methionine 
D  Aspartic acid  F Phenylanine 
C  Cysteine  P Proline 
Q  Glutamine  S Serine 
E Glutamic acid T Threonine 
G Glycine W Tryptophan 
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1.1 Antibodies: The New Era of Biologics 
Derived from the Immunoglobulin (Ig) family, antibody molecules are heterodimeric 
glycoproteins, produced by fully differentiated B-lymphocytes during the adaptive 
immune response. Antibodies target “non-self” molecules (antigens) such as pathogens, 
allergens, and toxins by interacting with an immunogenic sequence—epitope—within the 
foreign substance. Due to high affinity and specificity towards antigen and favourable 
characteristics such as solubility, stability and residual toxicity, therapeutic antibodies 
have driven the pharmaceutical industry with a pronounced market growth rate of 
biologics area through representatives in oncology, inflammatory/autoimmune and 
infectious disorders. In the last few years, antibodies volume approved and in late-stage 
development increased exponentially, representing ~75% of biopharmaceutical market in 
USA and Europe (BioPharma-Reporter.com). There are currently ~50 therapeutic 
antibodies for market sale, with seven ones being approved only in the former year, and 
over 280 in Phase II/III clinical studies.1   
1.1.1 Antibody Structure and Function 
In mammals’ immune system, the antibody format presents two identical heavy 
chains (H) and light chains (L) in Y-shaped structure (Figure 1.1). The L chains belong 
to kappa (κ) or lambda (λ) subtypes and H chains to α, δ, ɛ, γ or µ isotypes. The isotype 
is determined by sequence and length of heavy-chain constant domains, distributing 
antibodies among five classes: IgA, IgD, IgE, IgG and IgM, respectively.2 Because of its 
predominance in human serum, importance for immune response and excellent specificity 
characteristics, IgG constitutes the dominant format in immunotherapy and consequently 
the one being further addressed in the present thesis. In IgG class, each heavy chain is 
organized in three constant domains (CH1, CH2 and CH3) and one variable domain (VH), 
whereas the light chain is constituted only by a constant (CL) and a variable domains 
(VL). Variable domains are positioned into antibody N-terminus and together with the 
CL and CH1 regions constitute the fragment antigen-binding (Fab). This fragment is 
linked by a flexible sequence (hinge) to the CH2 and CH3 domains, constituents of the 
fragment crystallizable (Fc), where carbohydrates motifs are attached. Several inter-
domain disulfide bonds along with the highly conserved intra-domain ones maintain 
antibody integrity.3 
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Variable domains mediate antibody specificity and affinity towards antigen mainly 
through three hypervariable loops, named complementary determining regions (CDRs; 
H1, H2, H3, L1, L2 and L3), with the six CDRs of each antibody “arm” setting up the 
antigen-binding site (Fig. 1.1). CDR loops are supported by four relatively conserved β-
sheet strands, the framework sequences. The Fc region is the major responsible for 
antibody effector functions through complement and gamma Fc receptor (FcγR) binding. 
On the other hand, this IgG portion prolongs antibody half-life through a recycling 
mechanism dependent on neonatal Fc receptor binding.4 Considering the scope of the 
present thesis, this introduction section will be focused on antibody variable domains.  
 
Figure 1.1: Antibody IgG structure. 
Antibody molecule is divided into three major domains: two fragment antigen-binding (Fabs) and one fragment 
crystallizable (Fc). Each Fab comprises a variable fragment (Fv), constituted by antibody variable domains (VH and 
VL), one heavy-chain constant domain (CH1) and one constant light-chain variable domain (CL). Fc region comprises 
two heavy-chain constant domains (CH2 and CH3), represented in orange, responsible for complement and Fc receptor 
binding. The hinge region is represented in green. The inset represents a light-chain variable domain with the three 
complementary determining regions (CDR loops 1, 2 and 3). The arrows depict the β-sheet strands that form the CDR-
supporting regions (frameworks). The conserved disulphide bond within each variable light-chain is also represented. 
Adapted from Brekke & Sandlie.5 
1.1.2 Genetic Organization and Rearrangement of Antibodies 
During B-cells development, several mechanisms ensure the generation of an  
enormous repertoire of antibodies with ability to target highly diverse antigens (for review 
see Schroeder & Cavacini).2  
Antibody units (heavy-, κ light- and λ light-chains) are codified by multigene 
families divided into sets of tandemly arranged segments and situated on distinct 
chromosomal locations within the human genome. The diverse variable domains are 
assembled by combinatorial rearrangements of variable (V) and joining (J) genomic 
elements in case of light-chains and V, diversity (D) and J segments in case of heavy-
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chains. This process, termed somatic recombination, constitutes the prime source of 
antibodies variability. Additional diversity in form of nucleotide insertions and deletions 
occurs at segment junctions during V(D)J joining (junctional diversification). After 
recombinant connection of heavy and light chains, another source of antibody 
diversification, the fully assembled immunoglobulins are expressed as B-cell receptors 
(BCRs) at surface of newly generated mature cells, constituting the naïve antibody 
repertoire. 
 In the second phase of B-cells development, lymphocytes harbouring antigen-
specific immunoglobulins proliferate (clonal expansion) and undertake the second major 
mechanism of variability, somatic hypermutation, where randomly mutations occur at 
high rate in antibody variable domains. This antigen-driven activation of B-cells fine-
tunes the antibody response. Clones presenting beneficial mutations towards high-affinity 
antigen interactions undergo preferentially expansion and survival (affinity maturation). 
Along with B-cells activation, class-switch recombination originates a pool of antibodies 
with distinct heavy-chain isotypes and consequently variable biological properties. 
Finally, B-lymphocytes differentiate into long-lasting memory cells, responsible for rapid 
recall of immunologic response against the same antigen, or antibody-producing plasma 
cells. 
1.1.3 The in vivo Mechanisms of Action of Antibodies 
Antibodies exert their function in vivo through three main mechanisms: 
neutralizing/antagonist activity; receptor signalizing/modulation and cellular depletion 
through antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis (ADCP) and 
complement-dependent cytotoxicity (CDC) pathways.6 In the former action mode, 
antibodies directly bind to ligands such as cytokines, growth factors, pathogenic agents, 
and toxins, preventing the interaction of these molecules with their cognate receptors. 
Antibodies can also function as antagonist effectors, blocking receptor 
activation/function. On the other hand, receptor-antibody interactions may also induce 
the downregulation of the former expression at cell-surface, diminishing available 
receptors for activation, or modulate cellular fates/functions through activation cascades. 
Internalization of cellular receptors can as well be an indirect consequence of antibody-
mediated sequestration of respective ligands.7 The depletion of antigen-bearing cells 
includes the Fc-mediated antibody properties. These functions rely on Ig cross-linking 
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with cell-surface receptors and FcγRs on immune effector cells such as natural killer 
(ADCC) and phagocytic (ADCP) cells or on complement components (CDC), leading to 
the destruction, phagocytosis or lysis of target cells, respectively. 
1.1.4 Antibody Engineering: The Rise of Single-domain Antibodies 
In contrast to diversity of in vivo antibody response, specificity towards a single 
epitope is critical for safety and efficacy in therapeutics. Hybridoma technology enabled 
the production of the first pools of mouse antibody clones (monoclonal antibodies; mAbs) 
through fusion of antibody-producing cells and an immortalized cell line.8 Afterwards, 
DNA recombinant technology enabled the development of chimeric and humanized 
mAbs, which circumvented lack of effector functions as well as reduced immunogenic 
elicitation9 and half-life issues of mouse mAbs when applied in human therapeutics.10,11 
Finally, advanced strategies of genetic engineering including selection of antibodies from 
phage-displayed human libraries12 or immunized transgenic animals13 and human 
memory B-cells immortalization enabled the production of fully human mAbs, 
overcoming the remaining immunogenicity of chimeric and humanized mAbs (Fig. 1.2). 
 
Figure 1.2:  Evolution of antibody engineering. 
Yellow colored antibody represents mouse-origin, whereas blue color stands for human-origin. Mouse mAbs were 
produced by mouse hybridoma, being further genetic engineered through V gene cloning or CDR grafting into 
antibodies with mouse-origin restricted to variable regions or CDRs, chimeric and humanized mAbs respectively. 
Chimeric or humanized antibodies were generated and expressed in eukaryotic cells.  Fully human antibodies are 
selected by screening of in vitro antibody libraries or generated by hybridomas, where B-cells isolated from immunized 
transgenic mice for the human Ig locus are fused with myeloma fusion partners. Adapted from Brekke & Sandlie.5 
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Despite the quite successful application in therapeutics, large molecular weight 
(MW) of conventional IgG format impairs the targeting of sterically occluded epitopes 
and penetration into densely packed tissues. To overcome these major issues, smaller 
antibody scaffolds were developed such as Fab, single-chain variable fragment (scFv) 
and single-domain antibody (sdAb) (Fig. 1.3). Fab (~50 kDa) had previously been defined 
has containing the variable and CH1 domains of an antibody, whereas scFv (~30 kDa) is 
constituted by a VL-VH pair connected by a flexible linker, commonly (GGGGS)x.
14 In 
case polypeptide linker is absent or reduced, antibody fragments are denominated Fvs and 
tend to multimerise into diabodies and triabodies.14 sdAb constitutes the smallest 
functional fragment (~15 kDa), being constituted by the antibody VL or VH domains, 
and the only one whose antigen-binding site is restricted to three CDRs. Nevertheless, 
sdAbs demonstrated an affinity and specificity similar to the whole antibody format.15 
Moreover, fully-functional antibodies devoid of light chains were identified as natural 
constituents of camelid and shark immune systems.16  
 
Figure 1.3: Antibody fragmentation and alternative engineered variants. 
Left) Standard IgG format compared with camel IgG and shark IgNAR counterparts and their respective V domains. 
Right) Most common antibody fragments and their respective molecular weights as well as multimerize versions of 
the same. Adapted from Holliger & Hudson.17 
Innovative scaffolds of miniaturized antibodies have also been engineered by 
assembling distinct IgG formats and/or portions in one single molecule. Some examples 
are IgG-scFv fusion, scFab (single chain Fab), [scFv]2Fab, scFv-Fc, [(scFv)2Fc]2 
minibody/small modular immunopharmaceutical and di-dibodies (Fig. 1.4). 
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Figure 1.4: Alternative versions of antibody fragments. 
Adapted from Little.18 
 
1.1.4.1 Single-domain Antibodies as Therapeutic Molecules 
Single-domain antibodies, similarly to other antibody fragments, exhibit 
remarkable therapeutic advances relative to the classical IgG structure, in addition to the 
well-known biophysical properties shared with full-size antibodies. Minimal size of 
domain antibodies enables access to novel and cryptic epitopes, as surface proteins of 
infectious virus, and enhances tissue penetration/distribution, for example in tumours and 
blood-barrier crossing. Moreover, structural simplicity of single-domain antibodies 
allows a cost-effective manufacturing on prokaryotic systems as well as affinity and 
avidity improvements by basic engineering techniques. For example, individual sdAbs 
can be easily assembled in multimers (dimers, trimers and tetramers), where specificity 
could differ within each module.19 This formatting also contributes to half-life extension 
of sdAbs—rapid cleared from circulation because of low renal threshold. Nonetheless, 
other strategies can be applied to improve pharmacokinetic profile of sdAbs, including 
conjugation or fusion to albumin (plasma protein with extraordinary extended circulation 
time), polymers, carbohydrates or albumin-binding motifs.20 Domain antibodies can as 
well be re-formatted as Fc-bearing molecules, in cases Ig effector functions are desirable 
or even mandatory, although advantage conferred by microorganism production be 
compromised. Alternatively, sdAbs can be combined with small active moieties. 
Moreover, these effector domains could contribute to novel and specific/potent actions 
that surpass traditional antibody functions provided by the Fc portion. Active moieties 
include radionuclides, cytokines, toxins, enzymes, peptides, and proteins. In case effector 
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functions are dispensable, the absence of Fc receptor as occurs in minimal antibody 
fragments could provide an additional safety benefit through avoidance of 
immunogenicity, a central issue on full-IgG therapeutic applications. 
Given the relative conservation of framework regions, binding characteristics of the 
variable domains rely almost exclusively on CDRs sequence and length, being the second 
factor a primary determinant of binding-site shape. Nonetheless, majority of natural 
variable domains present length-constraint CDRs, only adopting a limited set of canonical 
conformations and consequently presenting a restricted capacity of antigen recognition.21 
Shorter loops favour the recognition of small antigens as haptens and peptides through 
deep pockets and grooves topographies (convex binding-sites), which contrasts with the 
more flat and protruding paratopes (longer loops) that preferentially target large antigens 
as proteins. Binding-site length also differ within each loop and chain type with L1, L3, 
H2 and H3 CDRs assuming an additional role on paratope topology. CDRs of light-chain 
domains commonly range from 7-13 aa, with some VLs presenting until 17/18 residues 
in L1 and/or L3. Binding-sites from heavy-chains mainly differ from 5-19 aa with some 
VHs presenting until 38 aa.21,22 Amino acid distribution also dictates preferential binding 
of CDRs and, similarly to length, each loop has its own unique composition and contact 
preferences.22,23 In general, tyrosine and tryptophan are the most common residues found 
on antibody binding-sites followed by isoleucine and serine. The remaining 
representativeness are more correlated with antigen type. For example, glycine, valine, 
cysteine, lysine, glutamate and phenylalanine residues are generally under-represented in 
protein and virus binders, whereas leucine and methionine are usually over-presented. In 
contrast with histidine, leucine and asparagine, alanine residue is most rarely found on 
haptens binding-sites. Residues position on binding-sites is also a factor on Ag-Ab 
interactions with the central amino acids, which are also the most variable ones, being the 
most involved in epitope interactions. The non-contacting residues are determinants for 
maintaining the conformational configurations of loops. Despite only 3% of sequenced 
variable domains being from non-human and -mouse origin, CDRs from distinct species 
also differ in binding and physical-chemical properties. For example, rabbit variable 
domains present greater variance in length and sequence as well as prevalence of long 
CDRs and a greater contribution of light chains for antigen binding than human and 
mouse antibodies.24 
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Antigen-binding strictly mediated by three CDRs such as in human-origin sdAbs  
exists naturally in antibodies belonging to Camelidae family and Cartilaginous fish 
class.25,26 The variable domains of these heavy-chain only antibodies (HCAbs) are 
denominated VHH for camelids and VNAR for sharks (Fig. 1.5). In contrast to the human 
gamma heavy chain disorder, where genetic deletions in VH and CH1 domains result in 
non-functional HCAbs,27,28 these unique antibody formats are capable of antigen 
recognition and binding. Moreover, extensive studies revealed peculiar chemical and 
biophysical characteristics of camelid-based VHs. The extension and structural flexibility 
of camelid CDRs compensate variability restriction from the absence of VL domains and 
suit propensity for cleft binding, a highly desirable feature to target structurally restricted 
regions oftentimes related with immune-evasion epitopes.29–31 On the other hand, these 
CDR features increase array conformations of VH domains, namely to non-canonical 
architectures, often improving VHH-antigen fit and consequently binding affinity.30 
VHHs are as well stable and soluble domains presenting no signs of aggregation when 
produced individually (nanobodies), which contrasts with the early isolated VH human 
domains.15 A major contributor to nanobody stability is the dissimulation of VH-VL 
interface through the presence of hydrophilic amino acids in conserved positions of this 
region.32 Extended CD3 can also bend backwards further shielding VL/VH region by 
interactions with framework residues30 although the expected negative impact of this 
feature in CDR3 diversity.33 An additional disulfide bond connecting CDR3 and CDR1 
or CDR2 loops, common in VHH domains, contributes as well to the stability of these 
non-standard VHs. Shark and camelid-based VHs share characteristics in terms of 
structure, biophysical properties and CDRs extension and plasticity.34–37 However, 
camelid domains have been further studied and therapeutically evaluated because of a 
higher homology degree with human VHs and easiness in isolation from naïve and 
immune libraries sources. 
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Figure 1.5: Structural comparison of canonical antibody format with camelid and shark heavy-chain only 
antibodies (HCAbs). 
Heavy-chains (H) are represented in blue and light-chains (L) in purple, with the constant (c) domains in lighter color 
and variable (v) ones in a darker version. In addition to light-chains, camelid HCAbs lack CH1 units. On the other 
hand, heavy-chains of shark HCAbs present five constant domains. Adapted from Doshi et al.38 
Despite tremendous stability and solubility along with remarkable refolding 
properties after exposure to high temperature, low pH stability and enzymatic 
degradation, VHHs are prone to immunogenicity when applied as therapeutic agents 
although no immune response was raised so far when these non-human VHs were applied 
in mouse and human therapy. In consequence, “camelization” strategies have been 
applied to engineer human VH domains39–44 in an attempt to minimize aggregation 
propensity15,45–48 and mimic biophysical properties of VHHs in terms of solubility, heat 
refoldability and purification yield.45 These strategies mainly consist in mutations to 
increase hydrophilicity of VL/VH interface and addition of non-native disulfide bonds.49–
54 Mutational changes on framework residues outside VL/VH interface or even CDRs 
itself constitute alternative approaches of “camelization”,33,55 sometimes resulting in 
engineered domains that rival the stability and cleft recognition of camelid ones.56 In 
alternative, stable human VH domains have been directly selected from antibody-based 
libraries, mainly through phage display technology.57–62  
Only sdAbs in form of VHH or human VH domains are currently under clinical trials 
development. A diverse array of camelid-based VHs are being studied against distinct 
targets within autoimmune, inflammatory, cardiovascular, respiratory, oncologic and 
neurologic diseases. Indicated for treatment of acquired thrombotic thrombocytopenic 
purpura (aTTP), caplacizumab is the leading VHH in product development pipeline 
(Table 1). A human domain antibody (GSK2862277) against tumor necrosis factor 
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receptor 1 is under Phase II evaluation for preventing acute lung injury and an albumin-
binding domain antibody (NCT02829307) has also been evaluated in Phase I as part of a 
strategy for half-life extension of rapid cleared drugs. 
Table 1.1: VHH domains under clinical development as December 2016. 
Adapted from Ablynx Inc. 
 
Although VH domains have been widely explored for human therapeutics, some 
studies demonstrated that VLs can present high expression yield, non-aggregation 
propensity46–48,63–68, reversibility of thermal unfolding and resistance to gastrointestinal 
proteases, in some cases better than VH domains.69 Previously, Brinkmann et al. had 
already described a VL domain as more active and less prone to aggregation than its VHs 
counterpart.70 These findings highlight the gap in exploration of VL formats potential for 
therapeutic applications. 
1.1.4.2 Phage Display Technology and Synthetic Libraries Tailoring 
Antibody development largely depends on implementation of display platforms. 
These in vitro technologies for the isolation of therapeutic candidates consist in three 
main steps: generation of a large repertoire of individual clones (library); display and 
selection rounds towards the target or desired property and functional screening and 
characterization of selected compounds (Fig. 1.6). Major display technologies include 
ribosome and mRNA/cDNA display, phage display and cell display.71 
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Figure 1.6: Display technologies flow-through. 
Iterative display and selection cycles (biopannings) diminish displayed-library size, being enriched for binders of 
interest targets. Post-selection modifications can complement function of selected binders or improve their biophysical 
properties. Adapted from Gálan et al.71 
Phage display is the most well-established technology for in vitro selection of 
antibody formats, relying in the presentation of functional proteins in fusion with viral 
coat proteins at surface of filamentous bacteriophages (phages).72 Genes coding for the 
surface-exposed molecules are encapsulated within the phage particle, establishing the 
phenotype-genotype linkage essential for the success of display technologies. In each 
selection cycle, phage-displayed library is subjected to selective pressure against a target 
molecule, usually immobilized onto a solid surface. Non-specific phages are washed out 
under stringency washing conditions, while phages of interest are eluted, enriched by 
infection and re-growth in bacteria (Fig. 1.7).  
 
Figure 1.7: Flow-through of phage-display selection cycle. 
A phage pool with great diversity containing the surface-displayed molecules and respective DNA coding sequences 
within the phage particles are incubated with an immobilized antigen (binding selection). Non-binding phages are 
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washed way, while specific ones remain bound to the antigen. These phages are afterwards eluted, being amplified in 
a bacterial host. Adapted from Sidhu & Koide.73  
Diverse types of antibody libraries can be subjected to in vitro selection and 
screening. A naïve library represents the natural immune repertoire of a donor, which 
variability relies only in sources of sequence variation during B cells maturation, mainly 
the rearrangements of V(D)J genes. Secondary lymphoid tissues harbor antigen-activated 
B cells, being a preferential source for additional diversity in a naïve repertoire. These 
libraries enable selection and isolation without knowledge of antigen structure or 
sequence. On the other hand, they present restrictions in selection of antibodies against 
non-canonical targets and heterogeneous representativeness of some gene 
combinations.74–76 For immunized libraries, recovery of plasma and activated B-cells 
occurs 5-6 weeks after animal inoculation with the desirable antigen. These libraries 
enable to direct the selection process towards current needs, although requiring antigen 
knowledge. Nonetheless, immunized repertoires limit selection of antibody clones 
targeting toxic, non-immunogenic, and self antigens in addition to non-standard ones. 
Immunization is as well a time-consuming process and results in an unpredictable antigen 
response. Due to ethical concerns, B cells collection is restricted to patients and non-
human animals. To overcome the limitations of naïve and immunized repertoires in 
antigen targeting, CDR sequences can be designed in silico and cloned into known 
antibody scaffolds, originating synthetic and semi-synthetic libraries. Synthetic libraries 
enable precise control over library variability and representativeness, providing de novo 
diversity and conformations, in addition to capability for in vitro screening of all antigen 
types.77 Nonetheless, the synthetic library should be rationally designed to maximize 
functional diversity and consequently library quality. This process is expected to reduce 
representativeness of misfolded, unstable, nonproper displayed and nonfunctional clones. 
Several strategies are available to the design/randomization of synthetic CDRs (reviewed 
in Neylon).78 Briefly, these methods introduce diversity in form of point mutations and 
insertions/deletions that can occur randomly or in specific positions of a target gene. In 
alternative, randomizing methods do not directly create de novo diversity, but combine 
the existing one in novel variants. At Fig. 1.8 is represented one technique from each 
category of CDRs design. 
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Figure 1.8: Strategies to design of synthetic CDRs. 
A) Error prone PCR introduces point mutations randomly within the target DNA being copied. B) DNA shuffling 
technique mixes fragments of distinct DNA sequences in novel combinations. C) Digestion & ligation technique 
introduces sequences of degenerate codons at specific positions of gene sequence. Adapted from Gálan et al.71 
CDRs tailoring for construction of synthetic libraries not only allows full control over 
clonal diversity as also gives insights into depth-knowledge of the molecular 
recognition/binding properties of natural binding-sites. For example, high-affinity clones 
with distinct specificities were selected from libraries with serious chemical restricted 
diversity.79–82 Consequently, it was concluded that only few amino acids are main 
contributors for CDR-mediated binding in minimalist synthetic proteins.83 One of these 
residues is tyrosine, whose structure in aromatic ring dominates the antigen interactions 
establishment. Previously, certain residues such as serine, glycine, histidine, arginine and 
tryptophan had already been described as substantially more frequent at binding sites than 
others.84,85 Overall, these studies outstand the targeting diversity of distinct antibody 
formats by using a limited set of residues. 
 
1.2 Human Immunodeficiency Virus 
Despite remarkable therapeutic advances, Acquired Immunodeficiency Syndrome 
(AIDS) continues to be a major public health and economic burden. According to 
UNAIDS (The Joint United Nations Programme on HIV/AIDS), ~36.7 million people 
were infected with HIV at the end of 2015 and ~1.1 million people died from AIDS only 
in this year. AIDS is characterized by an insidious deterioration of the cellular immune 
system, where a progressive depletion of CD4+ T-cells ultimately leads to the appearance 
of opportunistic infections (AIDS phase). Human Immunodeficiency Virus (HIV) is the 
etiological agent of AIDS,86,87 being divided in two types: HIV-1 and HIV-2.86–88 These 
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viruses differ in disease severity, evolution and transmissibility as well as prevalence and 
distribution worldwide. HIV-1 causes a more severe syndrome with a faster evolution 
towards the fatal AIDS phase and presents a higher transmission rate and prevalence. In 
contrast to worldwide distribution of HIV-1, HIV-2 is almost confined to West Africa 
even though the number of cases had lately increased in Europe, India and USA.89 HIV-
1 is classified in four groups: Major or Main (M), non-M and non-O (N)90, Outlier (O) 
and P91. The M group is the most prevalent and can be subdivided in clades from A-D, F-
H, J and K.92 These genetically distinct subtypes can in turn recombine and originate 
circulating recombinant forms (CRFs). HIV-2 is distributed through groups A to H, but 
only A and B cause AIDS epidemics, being the A group the far most prevalent worldwide. 
CRFs were also identified for HIV-2.93–95 HIV presents high variability intra and inter-
clades, a major reason for challenge design of drugs and vaccines, with an average 
nucleotide diversity of genomes being 50% between HIV types, 37.5% among HIV-1 
groups, 14.7% among clades, 8.2% within individual clades and less than 1% within 
single patients.96 
 
1.2.1 HIV morphology and genetic structure 
HIV-1 belongs to the Lentivirus genus of the Retroviridae family with a diploid 
genome of two positive single-strand RNA molecules that are reversely transcribed to a 
double-strand DNA molecule and integrated into host cell genome. HIV-1 also presents 
a lipid envelope acquired from the host cellular membrane during the virus budding. In 
this structure are embedded the viral envelope glycoprotein (Env) and several host-
derived membrane proteins.97 HIV-1 genome (Figure 1.9) codifies nine open reading 
frames (ORFs) flanked by long terminal repeats (LTRs) with the 5’LTR containing the 
HIV promoter.98–100 The group-specific antigen (gag), polymerase (pol) and env ORFs 
are translated as polyproteins precursors, with structural proteins being only codified in 
the gag and env genes. The gag gene originates the matrix (MA), capsid (CA), 
nucleocapsid (NC), p1, p2 and p6 proteins. Matrix protein overlays the lipid envelop 
internally, while capsid proteins shields the viral core through a coned-shaped structure 
and nucleocapsid units coat the HIV genome. ORF env encodes the gp160 precursor of 
Env, cleaved and processed during exportation towards cell-surface to originate gp120 
and gp41 subunits. Finally, the pol gene codifies the reverse transcriptase (RT), integrase 
(IN), and protease (PR) enzymatic proteins. The remaining six ORFs of the HIV-1 
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genome encode for viral accessory (Nef, Vif and Vpr) and regulatory (Vpu, Tat and Rev) 
proteins, being the last three not incorporated into HIV virion. In case of HIV-2, Vpu is 
substituted by Vpx (Fig. 1.9). 
 
Figure 1.9: Structure of HIV-1 genome (A) and organization of HIV-1 virion (B). 
Adapted from Shum et al. and Hedestam et al.101,102 
1.2.2 HIV replication cycle 
The replication cycle of HIV-1 is divided into infection and expression phases. 
Infection phase initiates with virus-cell interaction and concludes with the integration of 
proviral DNA into host genome. Expression of viral proteins triggers the second phase, 
which involves all steps until the budding and maturation of the virion (Fig. 1.10).  
HIV replication cycle initiates with the fusion of viral envelope and host cell 
membrane by engagement of viral glycoprotein Env to cell-surface receptors. This 
process culminates in the liberation of viral core into cell cytoplasm. Subsequently to 
uncoating, RT enzyme converts HIV genomic RNA into a linear double-stranded DNA 
molecule, which is imported to the cell nucleus and integrated into host cell genome 
through viral integrase activity. Short mRNAs originate the early viral proteins such as 
Tat, which in turn are responsible for driving the expression of late/structural proteins 
from the integrated HIV genome (provirus) using the cellular machinery. After 
expression, all viral components must travel along cytoplasm to the assemble location in 
specialized rafts domains of cell membrane. Assembly and budding of the new-born 
virions characterize the last stage of HIV replication cycle. During or shortly after cell 
release, protease enzyme promotes the cleavage of viral precursors into the individual 
constituents of HIV virion. This final step converts immature virions into their mature 
INTRODUCTION 
18 
 
infectious form. Viral accessory and regulatory proteins such as Vif and Vpx/Vpu assures 
replication cycle completion by counteracting the activity of several host restriction 
factors in arresting HIV infection. 
 
Figure 1.10: HIV-1 replication cycle. 
Interaction of viral envelope glycoprotein (Env) with cellular CD4 receptor and a chemokine co-receptor results in the 
fusion of virion envelope and cellular membrane. Following the fusion step, viral core release in cell cytoplasm 
(uncoating) results in reverse transcription of HIV genomic RNA into a dsDNA molecule. This viral cDNA together 
with several viral and cellular proteins is assembled into a pre-integration complex, whose nuclear import is mainly 
mediated by Vpr viral protein. In the nucleus, viral DNA is inserted into host cell genome through integrase activity, 
which concludes the infection/early phase of HIV replication cycle. Together with viral protein Tat, the long terminal 
repeat (5’ and 3’ LTRs) flanks of provirus have critical roles in transcription of HIV mRNA. This transcript can codify 
the genome of new-born virions or suffer alternative splicing to originate all viral proteins and polyproteins precursors, 
after being nucleus exported through a Rev-dependent pathway. Processing, assembling and maturation of novel viral 
particles occurs at cell membrane mainly through Gag and Gag-pol polyproteins and protease viral protein. Adapted 
from Peterlin and Trono.108 
The 5’LTR, where HIV promoter is allocated, is characterized by 3 regions: U3, 
R and U5. The U3 region contains the cis-acting regulatory elements of HIV promoter, 
being further divided into negative regulatory region, enhancer, and core promoter. Viral 
transcription initiates at R region and terminates with polyadenylation after R region of 
3’LTR. Several cellular transcription factors and viral regulatory proteins that interact 
with U3 region of LTR regulating HIV transcription are represented in Fig. 1.11. 
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Figure 1.11: LTR transcriptional activation. 
A) Localization of viral promoter on HIV genomic organization. B) The inset represents the viral transcription with 
cellular transcription factors such as NF-kB, SP1 and TBP and viral Tat binding to TAR sequence leading to P-TEFb 
assembly and consequent phosphorylation of RNA polymerase II (Pol II) CTD. Adapted from Caputi.104 
1.2.3 HIV-1 entry 
1.2.3.1 Env structure 
HIV-1 envelope incorporates the Env glycoprotein responsible for HIV tropism 
and entry. Env is composed by a trimer of gp120 surface glycoprotein non-covalently 
associated with gp41 transmembrane protein.  
Gp120 consists of five conserved (C1-C5) and five variable regions (V1-V5) 
distributed through two domains (Fig. 1.12). The conserved regions are concentrated in 
the inner domain, which constitutes the sterically occluded core of gp120, while variable 
regions—major contributors to immune-evasion—are highly glycosylated and mainly 
located at outer domain. Gp120 presents two crucial regions for HIV entry process, the 
receptor and co-receptor binding sites. CD4 membrane-spanning protein constitutes the 
prime HIV receptor.105–108 CD4 binding-site (CD4bs) is constituted by a hydrophobic 
cavity between inner and outer domains of gp120, well-conserved and devoid of 
glycosylation, thus a favorable target for HIV inhibition. CD4-bearing cells are the 
primary target cells of HIV infection, preferentially T-lymphocytes, but also 
macrophages, monocytes, dendritic and microglia cells. Of note, CD4-independent HIV-
1 infectivity has also been described.109 Co-receptor binding site is located within V3 loop 
of bridging sheet domain, only set-up upon CD4-gp120 engagement. This fact constitutes 
an additional immune-evasion strategy of HIV. The major co-receptors of HIV are CXC-
chemokine receptor 4 (CXCR4) and CC-chemokine receptor 5 (CCR5). 
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Figure 1.12: Structure of gp120 in CD4-bound conformation. 
The blue region represents the outer domain, whereas the orange-colored chain represents the inner domain. The green 
region is the bridging sheet domain composed of two pairs of anti-parallel β-sheet strands (two from each domain) and 
V1/V2 loop from the inner domain, only set-up upon CD4-gp120 engagement. CD4 binding-site, depicted as a red 
circle, is located between the inner and outer domains. Gp120 interacts with gp41 mainly through the inner domain and 
N/C terminal extensions.110,111 Adapted from Guttman et al.110  
Gp41 is constituted by three major domains: cytoplasmic tail, transmembrane 
anchor and ectodomain (e-gp41). Extracellular portion is the main mediator of HIV entry 
process in gp41 context. Gp41 ectodomain is characterized by a hydrophobic N-terminal 
fusion peptide (FP), two α-helix heptad repeat regions 1 and 2 (HR1 and HR2) and a 
membrane proximal external region (MPER). 
1.2.3.2 HIV-1 entry process: gp41 as fusion key 
HIV-1 entry, the first phase of viral replication cycle, begins with adhesion of viral 
particle to host cell through interaction of membrane proteins incorporated into viral 
envelope and attachment factors in host cell-surface. These contacts promote spatial 
approximation between viral glycoprotein Env and HIV receptor and co-receptor at cell-
surface. In a second phase, gp120 triggers the fusion process through binding to the 
cellular receptor CD4.105–108 CD4 interaction leads to rearrangements in gp120 such as 
the formation of a bridging sheet domain and exposure of V3 loop, both important for 
cellular co-receptor binding.112 Depending on the co-receptor used, HIV-1 is classified 
into R5 (CCR5 usage), X4 (CXCR4 usage) or R5X4 (both co-receptors usage) strains.113 
Alternative chemokine receptors were described as HIV-1 co-receptors, however there is 
no evidence for their role in vivo.114,115 Co-receptor engagement results in gp120 
dissociation from Env complex, leading to a cascade of conformational changes within e-
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gp41. Fusion peptide is released and inserted into the host cell membrane, originating an 
unstable e-gp41 conformation, named fusion intermediate structure. In this transient 
structure that quickly collapses into a less-energy state, termed six-helical bundle (6HB), 
HR1 and HR2 regions are conformationally exposed. 6HB conformation is characterized 
by the position of the three α-helix HR1 regions into a parallel fashion, forming the 
conformation core, and the three HR2 regions packed in an oblique and antiparallel 
manner into the highly conserved and hydrophobic grooves of the HR1 peptides.116–120 
Transition of e-gp41 to 6HB conformation drives the viral fusion process by bringing the 
virus envelope and cellular membrane in apposition, mediated by the retraction of the 
HR1/HR2 trimer of heterodimers.121 These alterations together with deformations in the 
plasmatic membrane triggered by gp41 FP and destabilization of the virus envelope by 
gp41 MPER lead to the formation of the fusion pore. The number of fusion pores needed 
to the successfully deliver of virus payload into the cells cytoplasm remains unclear. The 
HIV-1 entry process is represented in Fig. 1.13. 
 
Figure 1.13: HIV-1 entry. 
Viral Envelope (Env) is comprised by three gp120 and gp41 subunits (1). Gp120-CD4 interaction triggers the fusion 
process (2), causing conformational rearrangements in viral glycoprotein followed by co-receptor binding in variable 
loop 3 (V3) and insertion of gp41 fusion peptide into host cell membrane (3). The six-helix bundle formation concludes 
the fusion process (4). Adapted from Wilen et al.122 
1.2.3.2.1 Cell-Cell Spread of HIV 
HIV-1 transmission occurs through two routes: virus-cell and cell-cell. The virus-
cell was extensively explained previously and it is the most well-known process. Cell-
cell fusion is a more recently described HIV spread and its role and importance in the 
natural infection is still under debate. However, there are some studies that already 
demonstrated the efficiency and rapidity of this transmission mode in vitro, which 
anticipates a relevant if not dominant mode of the virus dissemination in infected 
individuals.123–129 
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Cell-cell fusion enables direct HIV spread from infected to non-infected target 
cells, establishing foci of infection. This route mainly occurs by formation of virological 
synapses (VS)130–135 with alternative mechanisms such as transient cell-cell contacts and 
longer-range intercellular interactions including nanotubes and filopodia136,137 
contributing residually. In VS mechanism, cytoskeleton polarization towards cell 
junctions is triggered by gp120-CD4 interaction (donor-target cells) leading to the 
formation of specialized structures, where viral proteins are redirected and 
concentrated.138 One question that remains unclear is related with HIV mechanism to 
penetrate target uninfected cell.  Since HIV entry is pH-independent, this process could 
simply occur by fusion between adjacent target cells (“fusion-from-without”). However, 
evidences suggesting an alternative, or even required, endocytic pathway for HIV entry 
have been reported.139–142 In this theory, virus fusion does not proceed beyond lipid-
mixing step at cell membrane level, requiring the formation of an endosomal 
compartment for viral capsid release on cell cytoplasm.140 
1.3 HIV/AIDS therapy 
Combination antiretroviral therapy (cART) constitutes the approved scheme for 
HIV treatment on seropositive/AIDS individuals, being composed by several 
antiretroviral drugs targeting multiple phases of the viral replication cycle. Available anti-
HIV drugs are distributed among five classes: nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTIs); non-nucleoside reverse transcriptase inhibitors (nNRTIs); integrase 
inhibitors (INSTIs); protease inhibitors (PIs) and entry inhibitors, which include the 
fusion inhibitors (Fig. 1.14). In current cART regiment, at least three compounds are 
prescribed simultaneously, usually two NRTIs combined with a PI or an INSTI, to 
maximize the therapeutic effect of HIV inhibitors and avoid resistance development in 
response to monotherapy. 
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Figure 1.14: HIV inhibitors at viral replication cycle. 
Adapted from Barre-Sinoussi.143 
Antiretroviral therapy is effective in suppressing viral loads and transmission 
rates, enabling the reconstitution of CD4+ cells count. However, this treatment fails to 
eradicate virus and consequently cure HIV-infected patients, implicating a lifetime 
treatment oftentimes associated with toxicity144 and persistent immune activation that 
result in age-related and metabolic disorders.145 On the other hand, the residual viremia 
present in cART-treated patients—highly derived from HIV latent reservoirs146–149—
results in one of the most common causes for therapeutic failure of cART, the emergency 
of resistant strains. In most cases, latency occurs when infected CD4+ T-cells return to a 
resting memory state, abolishing integrated provirus expression and establishing long-
lasting HIV reservoirs.146,147 Within these cellular reservoirs, HIV is ‘hidden’ from host 
immune system and antiretroviral agents, being responsible for viremia rebound and 
consequently de novo infection when latent cells are stimulated. The high mutational rate 
of HIV— related with error-prone nature of RT and virus rapid turnover—enables the 
selection of viral variants that escape the pressure of immune system and cART cocktail, 
providing them with a survival advantage. Polymorphisms among distinct HIV subtypes 
also influence virus susceptibility to inhibition and mutational resistance profile.150 In 
other cases, cost and number/route of administrations could lead to discontinuous therapy 
and consequently sub-optimal concentration of cART and accelerated resistance arose. 
Other limitation of cART is related with differences in inhibitory capacity of distinct HIV 
types.151 Only a few inhibitor classes such as NRTIs and INSTIs were described as active 
neutralizers of HIV-2 infection. Several PIs were potently compromised in inhibiting 
HIV-2, while nNRTIs and fusion inhibitors were in general ineffective. Specific 
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resistance to HIV-2 relates to differences between HIV types, limitations on HIV-2 
clinical trials and design/selection of antiviral inhibitors almost exclusively based on 
HIV-1 clades and isolates. Finally, another factor contributing to limit cART efficiency 
could be the non-standard transmission route of HIV. Considering the consensual 
importance of cell-cell spread for HIV dissemination in vivo, activity of antiretroviral 
compounds against this transmission mode vs classical one has been compared. In 
general, cART efficacy is similar between cell-cell and cell-free virus spread, being the 
NRTI class of inhibitors the most affected by transmission switch.152–154 Nonetheless, the 
massive concentration of viral particles in cellular contacts during cell-cell transmission 
could require a more efficient combination of highly active drugs. Cell-cell spread can 
also result in multiple integrated provirus and consequently originate novel recombination 
events and promote resistance strains appearance.155,156 Regarding the entry inhibitors, 
and despite reported efficacy in vitro, more studies have to be conducted since 
endocytosis requirement/role in cell-cell spread remains unclear.142,157,158  
In conclusion, and despite the increase in life expectancy and quality by cART, 
development of novel drugs continuous to be an urgent global need in HIV treatment. To 
reassure viral permanent and complete suppression, these therapeutic strategies have to 
be nontoxic, potent and effective against a broad spectrum of HIV subtypes as well as 
low-cost. One hypothesis consists in exploring novel classes of HIV neutralizers such as 
antibody, gene and RNA-based therapies against conserved/critical targets within virus 
replication cycle. A few ones are already under clinical trials development such as 
antibodies ibalizumab, an anti-CD4 entry inhibitor, and PRO-140 against CCR5 HIV co-
receptor, zinc-finger/nuclease tool (SB-728-T) for knockout of ccr5 gene or multiplexed 
RNAi molecules and alternative RNA-based agents (ClinicalTrials.gov; NHI USA). 
1.3.1 Inhibition of HIV Entry 
1.3.1.1 Entry inhibitors 
The latest HIV inhibitors approved by USA Food and Drug Administration target the 
entry step of virus replication cycle, constituting the only class that comprises pre-
infection drugs. This group has two members: T-20 against e-gp41 and maraviroc (MVC) 
targeting CCR5 chemokine receptor.  
T-20 peptide has 36 aa based on HR2 sequence (HIV643–678(LAI)) and blocks HR1-HR2 
interaction during gp41-mediated fusion by competing with HR1 for binding.159 
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Therefore, T-20 is the only fusion inhibitor of HIV in the biopharmaceutical market. 
Despite well-documented T-20 potency against distinct HIV-1 clades and cell-cell 
spread,160,161 issues have been associated with this inhibitor application in therapy. 
Resistance profile had emerged in treated patients, mainly related with mutations in a 
three amino acid sequence on HR1 region (GIV, 36-38 aa).162,163 Additionally, T-20 is 
currently the unique anti-HIV drug that lacks oral administration, requiring to be 
subcutaneously injected twice daily. HIV-2 susceptibility to T-20 seems also remarkably 
reduced compared with HIV-1.164,165 This last fact relates to several differences in 
structure, amino acid sequence and functionality of Env between HIV types. For example, 
HIV-2 entry process can be CD4-independent and mediated by alternative co-receptors, 
besides CCR5 and CXCR4, at least in vitro.166,167 These complications, together with high 
production cost,168 resulted in T-20 negligence on HIV therapeutic schemes.169 In 
addition, this peptide has only been residually tested as microbicide and PrEP (pre-
exposition prophylaxis) candidates, showing moderate results in preventing HIV 
transmission.  
Second and third-generation alternatives to T-20 such as T-649, Tifuvirtide, T2635, 
Sifuvirtide and C34 have been developed, being these peptides also derived from amino 
acid sequences overlapping HR2 and adjacent motifs (Fig. 1.15).170 However, and despite 
overall efficiency towards T-20-resistant strains, several mutations in HR1 have been 
described as decreasing or even abolishing HIV-1 susceptibility to these advanced HR2-
based fusion inhibitors.171 
 
Figure 1.15: Pairing of HR1 and HR2 on post-fusion state of gp41 (Top) and amino acid sequences of T-20 
(Enfuvirtide) and novel HR2-based fusion inhibitors (Bottom). 
X represents norleucine. Adapted from Menéndez-Arias.171 
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MVC binds a hydrophobic pocket in transmembrane region of CCR5 similarly to 
other antagonists of this chemokine receptor.172 MVC-CCR5 interaction results in 
conformational changes on receptor extracellular loops, blocking gp120 binding and 
consequently HIV fusion.172 Similarly to T-20, some drawbacks171 have been identified 
in MVC usage although reported efficacy in HIV treatment.173,174 In consequence of 
restricted inhibitory activity towards CCR5-specific viruses, MVC can promote the 
outgrowth of CXCR4-tropic variants known to accelerate CD4+ T cells depletion and 
consequently disease progression.175 Several mutations on gp41 and gp120, not restricted 
to V3 loop, have also been associated with clinical resistance to MVC,169 in addition to 
suggestion that higher doses of MVC are required to an efficient inhibition of HIV-2 
isolates compared with variants of type 1.164 Even though a few studies documented 
positive responses to MVC therapy in HIV-2 infected individuals, they were only 
conducted into ‘salvage’ therapeutic context.176,177 Considering all limitations and 
similarly to T-20, MVC is not a first-line antiretroviral agent, being only applied in 
‘aggressive’ therapeutic schemes for multidrug-resistant patients. Nonetheless, and 
despite recent failure in impairing SHIV infection of macaques,178 MVC is the only entry 
inhibition under clinical development (Phase II) for HIV prevention after fully protected 
humanized mice from HIV-1 challenge.179 MVC was also shown to protect humanized 
mice and macaques from SHIV infection when used as a microbicide, being currently 
tested under distinct formulations.180–182 
Since T-20 and MVC approval, several entry inhibitors reached clinical trials, mainly 
CCR5 antagonists but also CXCR4 and CD4 blockers as well as g120 binders. Two mAbs 
are also being evaluated as entry inhibitor against CD4 receptor and CCR5 coreceptor. In 
resume, and despite advances so far, there is an urgent requirement for novel entry 
inhibitors. 
1.3.1.2 Broadly Neutralizing Antibodies 
Elicitation of broadly neutralizing antibodies (bNAbs) constitutes a huge hurdle 
in HIV treatment/prevention. Despite capability of majority HIV-infected individuals to 
produce strain-specific neutralizing antibodies a few months after infection, circulating 
viruses escape the immune response through a mutation-driven process and ensure 
ongoing infection. The ineffectiveness of immune response against HIV infection is 
mainly related to structural and chemical characteristics of Env (Fig. 1.16).183 The outer 
domain of this viral glycoprotein presents antigenic diversity among HIV-1 clades184,185 
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and poor immunogenicity from extensive and shifting glycosylation. In contrast, 
conserved and critical-to-infection sites are conformational masked or steric occluded, 
being only transiently exposed during HIV fusion. Low density of functional Env 
complexes at virion surface combined with non-functional variants also contributes to 
HIV-immune escape. In a few HIV-infected individuals, the evolution of immune 
response though cycles of virus escape is believed to result in bNAbs production. By this 
way, these “elite controllers” (~1% seropositive individuals) are able to generate 
antibodies with in vitro cross-clade neutralization and aptitude to control virus replication 
and consequently delay AIDS onset in absence of cART.186 Several bNAbs against 
distinct targets within Env glycoprotein are represented in Fig. 1.16. 
 
 
Figure 1.16: Immune-evasion characteristics (Top) and broadly neutralizing antibodies (bNAbs) of HIV 
(Bottom). 
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Top) Antigenic variability of Env-surface residues within an individual during HIV infection timeline and among HIV 
strains and clades; the extensive presence of glycans at Env-exposed regions, creating a “shield” against the antibody-
mediated immune response; transient exposure of critical epitopes only during HIV fusion, for example membrane 
proximal region (MPER) on intermediate structure of gp41 and co-receptor binding site after gp120-CD4 engagement; 
conformational masking of, for example, CD4-binding site, sterical occlusion of critical sites to high molecular weight 
molecules such as antibodies; existence of non-function Env-complexes (non-cleaved Env precursors, gp41 six-helix 
bundles and gp120-gp41 monomers) and low density of Env molecules at virion surface. Bottom) Major targets of 
bNAbs on Env glycoprotein include CD4 binding site, V1/V2 loops, glycans at V3 loop, bridging region of gp120/gp41 
interface region and membrane proximal external region (MPER) in gp41. Adapted from Mouquet.183 
Overall, bNAbs can potently and broadly inhibit HIV infection in vitro, some of 
them with a neutralization potency (50% inhibitory concentration; IC50) of less than 1 
µg/mL and a neutralization breadth of >90% such as targeting-gp41 10E8 and CD4bs-
specific VRC01 and VRC02.187 As an exception, some bNAbs such as 4E10 and 2F5 
although presenting a potent and broad activity were reported as polyreactive, leading to 
an immune response against self and non-HIV antigens.188,189 Surprisingly, polyreactivity 
was more observed in gp41-targeting bNAbs than gp120-specific ones.190–194 On the other 
hand, rise of clinical resistance occurs more often for gp120-specific bNAbs. Regarding 
cell-cell spread, there is no consensus about bNAbs efficacy relative to this HIV 
transmission mode. While in vitro studies reported that only the most potent neutralizing 
antibodies, specific for CD4bs and V3 loop, efficiently inhibited cell-cell spread and even 
so with a concentration ten-fold higher than cell-free virus,195 in vivo studies seem to 
indicate a similar potency against the two possible spread modes.196–198 The exception are 
the gp41-MPER targeting bNAbs 4E10 and 2F5, which sensitivity seems decreased in 
simians infected with HIV/SIV chimeras (SHIV).199 Of particular interest was the  
broadly CD4bs-specific VHHs isolated from llama,200 namely the J3,201 and the potent 
N6 bNAb202. The former is capable of potently inhibiting cell-cell spread in vitro,203 
including neutralizing antibodies-resistant pathway between macrophage and T-cells,204 
while the second one was reported to circumvent common resistance mechanisms of HIV 
virus. Additionally to reported vireamia suppression in vivo,197,198,205 including human 
clinical trials,206,207 recent studies revealed bNAbs protection of humanized mice and 
macaques challenged with HIV or SHIV chimeras, respectively.208–217 Recently, Gautam 
et al. went further by demonstrating a long-lasting protection of several months, when 
macaques were repeatedly challenge with low doses of SHIV after single injection of a 
potent bNAbs cocktail.218 
Although remarkably potency in therapeutically and prophylactically impairment 
of HIV infection, neutralization escape has already been described for some bNAbs.205,216 
Nevertheless, peculiar features of these looked-for antibodies such as high number of 
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somatic hypermutations, including rare nucleotide insertions and deletions, prevalence of 
kappa light-chains and extended CDR3 loops on heavy-chain domains (20-35 residues vs 
14 residues)183 can give insights into structure and sequence signatures for rational design 
of HIV vaccines and next-generation inhibitors.  
An alternative scaffold to bNAbs is the dual-affinity re-targeting (DART) 
proteins, where the variable domains of distinct antigen-binding sites are incorporated 
into a disulphide-stabilized heterodimer. In the context of HIV therapeutics, diverse 
DART molecules, wherein one pair of variable domains recruits the cytotoxic T effector 
cells via CD3 receptor and the other one targets the HIV-1 Env on the surface of CD4-
infected cells, have originated positive results in viremia suppression and partial 
restoration of immune system functionality.219 Nonetheless, the safety and efficacy of this 
immune-inducible format have to be addressed in appropriate clinical trials. The recent 
advances on the engineering of chimeric antigen receptors (CARs) based on anti-HIV 
bNAbs also allowed to potentially target and kill infected cells despite absence of viral 
replication.220,221 Furthermore, in one of the studies T CD8+ cells harboring antiviral 
CARs were resistant to HIV infection due to ccr5 disruption through gene editing.220 
These results contrast with the failed attempts on clinical applications of CARs for HIV 
treatment in the late 1990s using the extracellular domain of CDR4 receptor.222 However, 
some clinical issues have been associated with CARs application such as the risk of 
toxicity223 and immunogenicity induction as well as lack of CAR persistence to control 
the appearance of viral resistance in HIV context.    
1.3.2 Inhibition of HIV Expression 
1.3.2.1 Small Interfering RNAs 
RNA interference (RNAi) is a post-transcriptional mechanism of gene silencing 
by which small RNA molecules, mainly small interfering and micro RNAs (siRNAs and 
miRNAs), induce degradation of target RNA messenger (mRNA).224,225 While miRNAs 
have to be transcribed from cell genome as primary miRNAs (pri-miRNAs) and 
afterwards converted into precursor miRNAs (pre-miRNAs) to be nucleus exported, 
exogenous derived double-stranded RNAs (dsRNAs) can be directly loaded into RNAi 
pathway to be processed by Dicer into short duplexes of ~21 nucleotides with two-
nucleotides 3’overhangs (siRNAs). These RNAi molecules are loaded into the RNA-
induced silencing complex (RISC), where passenger strand is uncoiled and discarded, 
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enabling the guide strand to direct the complex towards homologous mRNA. RISC-
endonuclease Argonaute arrests translation or cleaves target mRNA, leading to its 
consequent degradation. In contrast with miRNAs, siRNAs generally present full 
complementary with target mRNA and consequently single specificity (Fig. 1.17).226,227 
Mammalian cells employs RNAi pathway to regulate endogenous gene expression228 and 
to degrade invading viral RNAs although this last role is still under debate depending on 
cell and virus types. Besides naturally occurring RNAi regulators, mimics of pri- and pre-
miRNAs such as artificial miRNAs and short-hairpin RNAs (shRNAs) as well as 
synthetic dsRNAs and siRNAs can be engineered to trigger RNAi silence-specific 
pathway. 
 
Figure 1.17: RNA interference mechanism (RNAi) in mammalians. 
Left) Primary miRNA (pri-miRNA) is transcribed from cell genome and recognized by protein complex: Drosha and 
DGCR8. Drosha processes the pri-miRNA into the stem-loop precursor miRNA (pre-miRNA), which is transported by 
Exportin 5 from nucleus to cell cytoplasm. Pre-miRNA is cleaved by Dicer into mature miRNAs. Depending on miRNA 
complementarity with target mRNA, this can be degraded or its translation repressed. Right) Long double-stranded 
RNAs (dsRNAs) are processed into siRNAs by Dicer-R2D2 heterodimer, components of the RISC-loading complex. 
Processed RNA molecule is loaded into RNA-induced silencing complex (RISC), where passenger RNA (sense strand) 
is uncoiled and discarded by endoribonucleases Argonaute 2 (AGO2) and component 3 promoter of RISC (C3PO). The 
INTRODUCTION 
31 
 
remaining anti-sense strand guides RISC to the complementary target mRNA, which is cleaved by the AGO2 
endonuclease activity and subsequently degraded by exonucleases. Adapted from Davidson & McCray.229 
Triggering gene silencing exogenously through the usage of tailor-made 
molecules constituted a breakthrough in therapeutics.225 Despite origin, chemical and 
processing differences, all RNAi regulators present broad activity translated into virtually 
silencing of any interest gene, namely ‘non-druggable’ targets such as proteins lacking 
function or accessible conformation to conventional therapeutics.230 Nevertheless, 
synthetic siRNAs are expression-independent from DNA vectors and surpass the 
requirement for nucleus exportation and Dicer processing step, being directly loaded into 
RISC, even though Dicer-independent shRNAs had already been designed.231 
Accordingly, siRNAs are the most represented class of RNAi molecules in human clinical 
trials with activity in genetic and infectious disorders, cancer and ophthalmic 
conditions.232 Nonetheless, limitations continue to hold back RNAi application in 
therapeutics.  
Besides siRNA sensitivity to serum nucleases, off-target silencing233 although not 
yet documented in vivo, and activation of immune system,234 the lack of a specific and 
efficient delivery system continues to be the major challenge in RNAi therapeutics. With 
exception of particular cell types such as pulmonary epithelial cells that uptake siRNAs 
from surrounded environment,235 intrinsic characteristics of these minimal RNA 
molecules such as hydrophilicity and anionic nature are responsible for low cellular 
uptake. Moreover, siRNAs are too large to diffuse across membranes, but too small to be 
maintained in circulation, being rapidly cleared by kidney excretion.230 Even though 
chemical modifications have increased siRNAs half-life,236,237 this hurdle continues to be 
a major contributor to membrane-impermeable feature of these small RNA-based 
molecules. 
1.3.2.1.1 Strategies for Delivery of Small Interfering RNAs 
For some indications, local administration of siRNAs is sufficient to ensure a 
therapeutic effect as reported previously for intranasal, intraocular, intratumoral, 
intramuscular and intracerebral approaches in vivo.230 Nonetheless, systemic delivery is 
required to hamper some disease types, where target cells/tissues are inaccessible or 
widespread though human body. 
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The vehicles for systemic delivery of siRNAs can be divided into physical 
methods, viral vectors and non-virus based approaches. These systems can furthermore 
be classified into specific and non-specific methods. Physical vehicles of siRNA delivery 
include high-pressure injection238, electroporation239,240, ultrasound,241 and gene gun242. 
Although positive results in mice, safety issues limit the therapeutic usage of these 
methods. For example, high-pressure injection was reported to cause right-sided heart 
failure. An efficient alternative for the delivery of RNAi molecules are the virus-like 
particles such as adeno-associated virus (AAV), adenovirus, herpes virus and retrovirus 
(including lentivirus). However, ethical and safety concerns continue to retreat viral 
delivery methods, mainly the need for chromosomal integration of retroviral vectors—
the most common approach for stable expression of shRNAs. Viral vectors are also time-
consuming to produce, size-constrained in the case of AAVs and limited to deliver 
shRNAs and artificial miRNAs, which overexpression could cause cellular toxicity243,244 
and usage cannot be discontinued or altered in response to treatment evolution, disorder 
type or population heterogeneity. Non-viral methods represent the most advanced 
category in systemic delivery of siRNA molecules and the unique that include cell-type 
targeting. 
Specificity, namely through cell-surface receptor delivery, results in an efficiency 
increase and, simultaneously, side effects reduction of therapeutic siRNAs. These 
molecules can be chemical conjugated to cell-receptor ligands of non-antibody type or 
fused to antibody-based molecules targeting the cell surface.245 Common ligands of non-
antibody type include cholesterol,236 folic acid246 and aptamers.247–249 Regarding 
antibody-mediated delivery, Fabs and scFvs are among the most used targeting-
entities250–252 to avoid immune stimulation prompted by Fc region. siRNAs molecules can 
also be complexed with cell-penetrating peptides253 such as arginine-rich protamine and 
poly-arginine-peptides254 or polymeric255 and lipidic-based256,257 nanocarriers, which in 
turn can be decorated with targeting molecules such as antibodies. Surprisingly, RNAi 
molecules were also described to move between mammalian cells through connexin-
specific gap junctions, after donor cells were transfected with shRNA.258 Bacterial-
derived cells with no genome (minicells) were as well used to express or carry RNAi 
triggers.259 Delivery of RNAi molecules could be performed ex vivo, where target cells 
are isolated, treated with RNA-based molecule, and re-injected into the patient. Some 
non-based virus methods are represented in Fig. 1.18. 
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Figure 1.18: Non-based virus delivery systems and cell-surface receptor delivery pathway of siRNAs. 
(Left). Cell-specific delivery of siRNAs can be mediated by cholesterol and other ligands of cell-surface receptors. 
Cell surface-targeting aptamers and antibodies can also be fused with siRNAs. These RNAi molecules can also be 
encapsulated in lipid nanoparticles decorated or not with cell-surface antibodies (SNALPs and immunolipossomes, 
respectively). (Right). Antibody recognizes and binds a cell-surface receptor, which internalizes through endocytosis, 
siRNA escape from endossome and is loaded into RISC-loading complex. Adapted from Dominska & Dykxhoorn.260 
Even though there is no ‘ideal’ method for in vivo siRNA delivery, since it depends 
on targeting cell-type, location and desirable therapeutic effect, antibody-mediated 
delivery seems to gain ground relative to others delivery approaches, mainly to liposome-
based methods known to easily trigger diverse inflammatory pathways261 and difficult 
intracellular release of siRNA.256 
1.3.2.1.2 Small Interfering RNAs in HIV Therapeutics 
A diverse array of therapeutic siRNAs targeting key phases of HIV infection has been 
developed (database http://crdd.osdd.net/raghava/hivsir/),262 being conservation of RNAi 
target crucial to avoid clinical resistance. RNAi therapeutics theoretically allows to target 
any sequence within HIV genome, which clearly exceeds cART capability. Moreover, 
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potency of RNAi, mainly when distinct regulators are multiplexed as a single therapy, 
can decrease dosage requirement and consequently possible off-target effects. 
Several RNAi triggers were reported to efficiently suppress HIV in cell lines as well 
as primary T-cells and macrophages. However, the lack of an efficient and cell-specific 
delivery system impairs a potent therapeutic effect in vivo. This fact is even more dramatic 
in the context of HIV infection because of T-cells known resistance to lipid-based 
transfection. Accordingly, viral vectors constitute the prime choice for delivery of RNAi-
based therapeutics in HIV and the unique strategy recently on clinical trials development, 
but only as ex vivo approaches.261,263 In DiGiusto et al.,264 haematopoietic progenitor cells 
isolated from peripheral blood were transduced with a single lentiviral vector expressing 
an anti-tat/rev shRNA, a CCR5-targeting ribozyme and a nucleolar localizing TAR decoy 
and afterwards re-injected into patients with AIDS-related lymphoma. In addition to 
tat/rev mRNA degradation induced by shRNA, catalytic ribozyme cleaves CCR5 mRNA, 
while TAR decoy sequesters Tat from its cognate target on HIV promoter. On the other 
hand, Symonds and co-workers265 developed a self-inactivating lentiviral vector 
codifying an anti-CCR5 shRNA and the fusion inhibitor peptide C46, which were 
transduced in hematopoietic stem/progenitor and CD4+ cells. Like cART, a combinatorial 
approach with multiple and distinct targeting molecules is expected to prevent emergency 
of RNAi-resistance virus and to compromise viral fitness of possible escape variants. 
Nevertheless, safety issues resulting from expression, integration and induction of 
interferon responses along with difficulties in maintaining stable transgene expression in 
progeny T-cells for impairment of HIV resistance have been attributed to shRNA-based 
delivery methods.266–272 Moreover, an shRNA-based therapeutic scheme is unable to be 
adapted in response to escape viral mutations. Consequently, diverse strategies were 
already tested for the delivery of anti-HIV siRNAs, where antibody-mediated approaches 
stand out among these.  
Regarding antibody-mediated delivery, Kumar et al. successfully delivered anti-HIV 
siRNAs to humanized mice through targeting T-cells CD7 marker with a scFv-9arginine 
peptide.273 Previously, Song et al. had already fused a Fab antibody fragment with RNA-
binding protamine to specifically deliver a siRNA against tat mRNA through viral gp120 
glycoprotein. Additionally, this fusion protein suppressed tumour growth when loaded 
with anti-oncogenic siRNA and injected into mice harbouring Env-expressing tumour.250 
Likewise, others targeted gp120 to deliver anti-HIV siRNAs, this time with aptamer-
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siRNA chimeras that suppressed viral load and restored CD4+ count.274,275 CD4 aptamer-
siRNA chimeras were also reported to protect humanized mice from HIV sexual 
transmission, when applied as microbicide.276,277 Immunoliposomes were as well 
described as effective in the delivery of therapeutic siRNAs to HIV prime targets in 
humanized mice.278 Some non-targeting strategies have been under development for anti-
HIV siRNA delivery such as electroporation and polymer, lipid and dendrimer 
nanoparticles.261 All these methods present advantages and disadvantages. For example, 
antibodies and aptamers can residually protect siRNAs from serum nucleases, but provide 
an efficient and targeted delivery, diminishing side-effects occurrence. On the other hand, 
aptamer-siRNA chimeras lack of immune activation is counteracted by its rapidly 
clearance though kidney excretion.279 On the contrary, antibody-siRNA constructions 
may trigger host immune system, but they are maintained long time in circulation. 
Targeted nanocarriers such as immunoliposomes can increase siRNA stability in serum 
but at the same time may stimulate a strong immune response. Non-targeting strategies, 
in addition to lack of specificity and consequently a decrease in efficiency, have tendency 
to induce interferon responses, mainly lipid nanoparticles, and in case of naked siRNAs 
present short half-life and bloodstream instability.  
1.3.2.2 Artificial Transcription Factors Based on Zinc-finger Proteins 
Zinc-finger proteins (ZFPs) comprise one of the most important and frequently 
codified class on eukaryotic genomes. ZFPs are constituted by tandem repeats of small 
motifs, the zinc-finger domains, being each one stabilized by hydrophobic interactions 
and the coordination of a Zn2+ ion. These peculiar proteins also present a tremendous 
diversity in structure and function, capable of interacting with diverse biological 
macromolecules including DNA, RNA, proteins, and lipids. Specific-nature of DNA-
binding capacity is one of the most interesting and characterized feature of ZFPs, mainly 
Cys2His2 family. Cys2His2 domains have normally ~30 aa in length and present a 
characteristic ββα structure comprising two conserved cysteines and histidines residues, 
which are responsible for zinc binding and consequently ZF stabilization (Fig. 1.19).280 
Zinc-finger domains recognize 3-4 bp of target DNA duplex. Key positions -1, 2, 
3 and 6 on helix portion, known as recognition helix, are the main determinants of DNA-
binding specificity (Fig. 1.19)280–283 although the importance of a fifth nucleotide-residue 
contact was recently hypothesized.284 Nonetheless, non-canonical interactions of these 
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positions and the role of flanking residues should not be unvalued, forward requiring the 
confirmation of designed ZFPs specificity for target DNA.285,286 Individual zinc-finger 
domains with distinct specificities can be covalently linked in tandem repeats (polydactly 
ZFPs) to recognize extended stretches of DNA, theoretically targeting any sequence of 
interest.287 Liu et al. was the first to validate the targeting of 18 bp DNA stretches, 
generally unique in human genome, by assembling two three-fingered proteins via ZFPs-
naturally occurring linker TGEKP288 although non-canonical linkers have also been 
used.289–291 Recently, DNA-binding domains covering all possible 64 combinations of 
genetic code were identified through systematic screenings of large synthetic ZF 
libraries.284 Together with the already available zinc-finger sets from Barbas 
laboratory,292 Sangamo BioSciences293 and ToolGen294 companies, this discovery 
extends ZFPs application to a brand new level.  
 
Figure 1.19: Structure of a zinc-finger domain and interactions between zinc-finger protein and DNA. 
Structure of ZFP-DNA complex (Left). The zinc-finger protein with three zinc-fingers 1, 2 and 3 (red, yellow and 
violet) binds the major groove of DNA (blue). The grey spheres represent the Zn2+ ions. Sequence-specific binding of 
DNA-ZFP (Right). The recognition helices are represented as squares in diagram centre. Key residues for ZF-DNA 
binding (positions -1; 2; 3 and 6 in surface of ZF α-helix) are represented by single-letter code. Dashed lines represent 
the interactions between zinc-fingers and the two strands of DNA. ZFP binds three contiguous nucleotides of DNA in 
3’-5’ orientation, with a possible forth interaction with the adjacent strand. Adapted from Gaj et al.295 and Jamieson et 
al.296  
Individual zinc-finger domains can be selected from combinatorial libraries, 
elected among the natural available repertoire or rationally designed, being afterwards 
modularly assembled towards desirable DNA sequence.296–298 Alternative engineering 
methods for ZFPs design manage the context-dependent interactions by considering the 
entire sequence of target DNA instead of each triplet individually. Some examples are the 
bipartite,299 sequential,300 bacterial “two-hybrid”301 and oligomerized pool engineering302 
methods. In general, these second-generation strategies improve quality of resulting 
DNA-binding proteins although cost and complexity are oftentimes increased. To make 
the most of customized ZFPs, these multimers of DNA-binding domains can be in vitro 
associated with functional moieties such as nucleases, recombinases, transposases, 
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methyltransferases, integrases and transcription factors (Figure 1.20).287,303–309 One major 
application of synthetic zinc-fingers is on modulation of gene expression. Artificial 
transcription factors (ATFs) activate or repress target genes depending on engineered 
fused domain. For example, six-fingered proteins fused with the tetrameric repeat of 
herpes simplex VP16 activation domain (VP64) up-regulated expression of epidermal 
growth factor receptor 2 and 3 genes, while fusion with Krüppel-associated box (KRAB) 
resulted in their repression.310 ZFPs alone can also repress gene expression by sterically 
occluding transcription elongation or initiation and co-activators binding.308 Additionally, 
site-specific methylation mediated by ZFP-methyltransferase can trigger gene silencing 
pathways.311  The efficacy of ZF-based artificial regulators in activating or repressing 
gene expression have been validated in several in vitro288,306,312,313 and in vivo314,315 
models.  
 
Figure 1.20: Applications of zinc-finger proteins in genome engineering. 
Zinc-finger proteins can be fused or linked to nucleases such as FoxI to cleavage target DNA, recombinases, 
transcription factors such as VP64 activator or KRAB repressor to regulate gene expression, and methyltransferases. 
Adapted from Gersbach et al.292 
1.3.2.2.1 Strategies for Delivery of Zinc-finger Transcription Factors 
Virus-like particles (limitations described in section 1.3.2.1.1 Strategies for 
delivery of small interfering RNAs) together with toxicity-related316,317 transfection and 
electroporation methods318 have been the most common carriers of ZFPs319–322 until a 
breakthrough report from Gaj et al. described zinc-fingers as naturally cell-penetrating 
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domains.323 Moreover, the same authors reported efficient ZFPs-mediated delivery of 
functional large proteins into cytoplasm of diverse mammalian cell types.295 Recently, a 
ZF-based ATF was even capable of cross the blood-brain barrier and restore the 
expression of a brain endogenous gene, when fused with the well-known HIV Tat cell-
penetrating peptide.324 Accordingly, Liu et al. had previously observed that cell-
permeability of zinc-fingers was enhanced by incorporation of successive nucleolar 
localization signals (NLS)—highly positively charged peptide known to innately cross 
cell-membrane.325 Nevertheless, some laboratories are still reporting virus-based 
approaches to successfully deliver zinc-finger based effector molecules, mainly 
nucleases.326–328 These findings, together with the fact that zinc-fingers constitutes 
currently the most represented genome engineering tool under clinical trials development 
(NCT0047693),329 enhanced the powerful application of these zinc coordinated domains. 
1.3.2.2.2 Zinc-finger Transcription Factors in HIV Therapeutics 
ATFs assume a significant role in HIV inhibition, since genome editing 
therapeutic efforts have proven difficult to overcome the rapidly viral escape provided by 
high mutation rate of RT or could even contribute for acceleration of resistance 
development.330,331 Although the importance of transcription activators in hijacking HIV 
latency, this thesis will focus on role of repressor ATFs for the inhibition of HIV 
transcription and replication. Several repressor ATFs were already developed to 
shutdown LTR promoter and therefore prevent viral proteins transcription and completion 
of HIV replication cycle.332,333 One of the most potent antiviral ATFs described was 
KRAB-HLTR3,333 which presents the well-known repression domain KRAB334,335 as 
effector molecule. KRAB seems to present the most potent transcriptional  repressor 
activity, when compared with other repressor domains such as ERF repressor domain or 
mSin3 interaction domain.310,333 KRAB-HLTR3 could inhibit HIV replication in cell lines 
as well as primary cells with potent activity. This potency can also be explained by the 
overlapping of HLTR3-binding site and two SP1-binding sites on HIV promoter, leading 
to the competition between KRAB-HLTR3 and SP1 transcription activator for LTR 
binding. Another ATF, designed to target the highly conserved tRNA primer-binding site 
(PBS) on LTR promoter, reported to inhibit HIV replication in primary T-cells.332 Other 
ATFs were developed to target PBS region and SP1-binding sites on HIV promoter, 
resulting in the inhibition of viral transcription and replication.336,337 In all these reports, 
transfection and lentiviral methods delivered the anti-HIV ATFs. 
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There are currently no ATFs under clinical trials development against HIV 
infection, only a zinc-finger nuclease targeting CCR5 gene is currently being tested as an 
ex vivo approach. In this strategy, autologous CD4+ T-cells modified with viral vector 
codifying therapeutic zinc-finger-nuclease gain resistance to HIV R5 infection.338,339  
In general, lack of potency and breath as well as specificity in targeting/delivery 
of HIV therapeutic molecules continue to be major hurdles in treatment/eradication of 
AIDS disease. In this thesis, we propose to contribute for the closing of these gaps through 
the engineering of innovative antibody-based molecules. 
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2.1 Abstract 
Objective: To develop a novel and potent fusion inhibitor of HIV infection based on a 
rational strategy for synthetic antibody library construction. 
Design: The reduced molecular weight of single-domain antibodies (sdAbs) allows 
targeting of cryptic epitopes, the most conserved and critical ones in the context of HIV 
entry. Heavy-chain sdAbs from camelids are particularly suited for this type of epitope 
recognition because of the presence of long and flexible antigen-binding regions 
[complementary-determining regions (CDRs)]. 
Methods: We translated camelid CDR features to a rabbit light-chain variable domain 
(VL) and constructed a library of minimal antibody fragments with elongated CDRs. 
Additionally to elongation, CDRs’ variability was restricted to binding favorable amino 
acids to potentiate the selection of high-affinity sdAbs. The synthetic library was screened 
against a conserved, hidden, and crucial-to-fusion sequence on the heptad-repeat 1 (HR1) 
region of the HIV-1 envelope glycoprotein. 
Results: Two anti-HR1 VLs, named F63 and D104, strongly inhibited laboratory adapted 
HIV-1 infectivity. F63 also inhibited infectivity of HIV-1 and HIV-2 primary isolates 
similarly to the US Food and Drug Administration-approved fusion inhibitor T-20 and 
HIV-1 strains resistant to T-20. Moreover, epitope mapping of F63 revealed a novel target 
sequence within the highly conserved hydrophobic pocket of HR1. F63 was also capable 
of interacting with viral and cell lipid membrane models, a property previously associated 
with T-20’s inhibitory mechanism. 
Conclusion: In summary, to our best knowledge, we developed the first potent and broad 
VL sdAb fusion inhibitor of HIV infection. Our study also gives insights into engineering 
strategies that could be explored to enhance the development of antiviral drugs. 
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2.2 Introduction 
Significant advances in antiretroviral therapy have occurred as the approval of the 
first fusion inhibitor, T-20.340 T-20 peptide derives from the C-terminal region (HR2) of 
gp41 fusion protein from HIV643-678(LAI).
341,342 By competitively binding the N-terminal 
region (HR1), T-20 impairs HR1-HR2 interaction341 and consequently the formation of 
the six-helix bundle (6HB) structure, responsible for HIV fusion (reviewed in Wilen et 
al.122). Despite the well-characterized antiviral potency of T-20, clinical resistance has 
been reported in HIV-1-infected patients.163 Additionally, T-20 is described as 
antigenic,343 highly expensive, protease-susceptible (no oral administration) and 
“pharmacokinetically limited”, among other limitations.168 Overall, development of 
novel HIV fusion inhibitors with improved biophysical and pharmacokinetic properties 
is required. 
Antibody fragments emerged to overcome issues associated with high-molecular 
weight of native antibody structure (IgG), mainly the targeting of cryptic epitopes and the 
penetration into densely packed tissues. Single-domain antibody (sdAb) is currently the 
smallest functional antibody fragment, only constituted by the antibody heavy-chain or 
light-chain variable domains (VH or VL).15 Additionally to the reduced size, 
complementary-determining regions (CDRs; antigen-binding regions) of sdAbs can be 
easily engineered to develop specific and high-affinity binders. sdAbs also present 
excellent biophysical properties such as high stability, solubility and low toxicity.344 
Despite these beneficial features, only the therapeutic potential of VH domains have been 
intensively explored.345 Nevertheless, several reports have demonstrated that VL domains 
present excellent biophysical properties such as high expression yield, resistance to 
aggregation and proteases, stability and high reversibility of thermal unfolding, in some 
cases better than VHs.47,48,63,69 Moreover, the stability of VL domains was further 
evidenced by the proved functionality of these sdAbs in the absence of disulfide bonds46,64 
or in the reducing cellular environment65,66. 
Here, we engineered a VL sdAb with elongated CDRs that broadly and potently 
inhibits HIV-1 infection by targeting a well conserved and crucial-to-fusion sequence on 
HR1. Despite the clinical resistance to HR1-targeting T-20, this region contains highly 
conserved residues among HIV-1 subtypes and isolates,116 representing a major target to 
HIV infection impairment. Anti-HR1 VLs were selected by phage display technology 
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from a restricted combinatorial library. Epitope mapping of the two most potent antiviral 
VLs—selected against an HIV-1 laboratory-adapted strain—showed that these inhibitors 
target a highly conserved and critic region within HR1. One VL (F63) showed high 
potency to inhibit HIV-1 and HIV-2 primary isolates with comparable T-20 activity. For 
last, we demonstrated that F63 also interacts with lipid membranes, a key ability of potent 
HIV entry inhibitors346,347 that correlates with their mechanism of action. 
 
2.3 Materials and Methods 
2.3.1 N36 antigen 
N36 was synthetized (Thermo Fisher Scientific) based on HIV-1 strain HXB2Env546-
581 and solubilized in 40% (v/v) DMSO at 1 mg mL
-1. 
2.3.2 VL construction plasmids 
Modified pT7-FLAG-2 plasmid (Sigma-Aldrich) with the cloning sequence from 
pComb3X plasmid (ompA peptide leader to amber stop codon) inserted into 
HindIII/BglII sites was obtained from Technophage, Lisboa, Portugal. 
The anti-HEL VLs were generated by PCR through the CDR3 grafting of a stable 
rabbit dAb348 derived from a scFv specific for HIV-1 Vif protein349. VL sequence used as 
template was the following: 5’-
GAGCTCGTGCTGACCCAGACTCCATCCTCCGTGTCTGCAGCTGTGGGGGGCA
CAGTCACC 
ATCAATTGCCAGGCCAGTCAAAGTGTTTATAATAACAACAACTTAGCCTGGT
ATCAGCAGAAACCAGGGCAGCGTCCCAAGCTCCTGATCTATGGTGCATCCG
ATCTGGCATCTGGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGGGACAC
AGTTCACTCTCACCATCAGCGGCGTGCAGTGTGCCGATGCTGCCACTTACTA
CTGTCAAGGCGAATTCAGTTGTGTTGGTGGTGATTGTTTTGCTTTCGGCGGA
GGGACCGAGCTGGAGATCCTA-3’. Each VL construction was originated by 
assembling of two purified PCR fragments (example: CDR3 22 aa F fragment x CDR3 
22 aa R fragment; Table 2.1) by PCR overlap. PCR-overlap fragments were inserted into 
the SfiI sites of modified pT7-FLAG-2. VL sequences were verified by DNA sequencing 
analysis. 
Anti-HR1 VLs were cloned into the NheI/XhoI sites of pET-28a (+) (Novagen, Merck 
Millipore; primers sequence in Table 2.1 Supplementary Information). F63 dimer with a 
medium linker (ML, [GGGS]2) was constructed by a restriction/ligation strategy 
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previously described in Oliveira et al.350 Briefly, two PCR fragments were originated 
(F63 monomer N-terminal and F63 monomer C-terminal, Table 2.1 Supplementary 
Information), digested by NotI and assembled together. The resulting fragment was 
inserted into the Nhe/XhoI sites of pET28a (+). 
2.3.3 ELISA measurements 
ELISA assays were performed as described.43 Briefly, high-binding plates (Costar 
3690, Thermo Fisher Scientific) were coated with 1 µg of hen egg-white lysozyme (HEL; 
Sigma Aldrich)/bovine serum albumin (BSA) or high-adsorption peptide plates 
(Immobilizer-amino plates, Nunc, Thermo Fisher Scientific) were coated with 500 ng of 
N36/BSA according to manufacturer’s instructions. After blocking with PBS-BSA, 500 
ng of purified VLs were added to the wells and further incubated. VLs were detected by 
a HRP-conjugated anti-HA monoclonal antibody (anti-HA-HRP; Roche Diagnostics). 
For the competitive ELISA, 30 pmol of VL constructions were incubated with different 
quantities of HEL or N36 peptide in solution at 37 ºC.  After 1 h, this mixture was added 
to HEL or N36-coated wells and further incubated. For epitope mapping, immobilizer-
amino plates were coated with 1 µg of each HR1 peptide from HIV-1 Clade B (MN) Env 
Peptide Set (NIH AIDS Reagent Program)/BSA according to manufacturer’s instructions. 
After BSA-PBS blocking, 100 ng of purified VLs were added to the wells and further 
incubated during 1 h at 25 °C.  
2.3.4 Library construction and selection 
Synthetic library was generated using the VL derived from the anti-Vif scFv349 as 
scaffold and accommodating a maximum of 22 aa in CDR1 and CDR3. Briefly, CDR1 
randomization was first introduced by two PCR amplifications (primers sequences in 
Table 2.1 Supplementary Information), using the DVN degenerate codon. D codifies for 
bases A, G or T; V codifies for bases A, C or G and N codifies for bases A, C, G and T. 
The amino acid distribution for the DVN codon can be found in CodonCalculator 
algorithm (http://guinevere.otago.ac.nz/cgi-bin/aef/CodonCalculator.pl).351 The two PCR 
fragments were subjected to PCR overlap (primer sequences in Table 2.1 Supplementary 
Information). The resulting PCR product was then submitted to a second round of 
amplification to introduce the randomization in CDR3 (primers sequences in Table 2.1 
Supplementary Information). The final PCR product was cloned into the SfiI sites of 
pComb3X phagemid (provided by C. Barbas III), designed to display recombinant 
proteins on the surface of filamentous phage M13 in a monovalent format 352. The 
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synthetic library represented by ~8.0x109 independent clones was transformed into the 
amber-stop codon suppressor strain Escherichia coli (E. coli) K12 ER2738 (New England 
Biolabs) that allows the expression of the synthetic VLs in fusion with phage p3 surface-
protein. 
Selection of VLs against HR1 peptide was performed by phage display technology, 
as previously described 353. Briefly, phages from the library were cycled through three 
rounds of binding selection (pannings) against HR1-coated 96-well Immobilizer-Amino 
Plates (Nunc, Thermo Fisher Scientific). Adsorption of HR1 peptide was performed 
according to manufacturer’s instructions, using decreasing quantities of antigen 
throughout the pannings (1000 ng in the first, 750 ng in the second and 500 ng in the third 
panning). Phages expressing the recombinant VLs were incubated with HR1 peptide 
during 2 h. Washes were performed five times with PBS-Tween 20 0.05% (v/v). Bound 
phages were eluted with trypsin for 30 min and then amplified in E. coli K12 ER2738 
with the addition of VCSM13 helper phages (Agilent Technologies). The third panning-
selected VLs pool was cloned into previous inserted SfiI sites of pT7-FLAG-2 expression 
vector and transformed into E. coli BL21 (DE3) (Invitrogen, Thermo Fisher Scientific). 
For protein expression, individual clones from the third-panning were grown in round-
bottom 96-well plates using the Overnight Express Auto-induction System 1 (Merck 
Millipore) according to manufacturer’s instructions. After overnight expression, cells 
were lysed with BugBuster Protein Extraction Reagent (Merck Millipore) and cell 
extracts harvested through centrifugation. ELISA screening was performed as described 
above, using 500 ng of HR1 peptide as antigen. The five clones that presented more 
binding to HR1 peptide over BSA were subjected to DNA sequence analysis. 
To the anti-HIV screening, 1 µg of bacterial extract from the five anti-HR1 VLs 
selected by phage display and ELISA were incubated with 40 000 infectious units (IU) 
of HIV-1NL4-3. After 3 h at 37 °C, 40 000 TZM-bl cells were infected with the 
HIV/inhibitors mixture. The medium was changed 3 h after infection. At 48 h post-
infection, β-galactosidase expression was quantified as described.43 
2.3.5 VLs expression and purification  
VLparental was provided by Technophage, Lisbon, Portugal. Anti-HEL VL 
constructions were transformed into E. coli strain BL21 (DE3) cells and expressed to the 
bacterial periplasmic space due to the presence of OmpA leader from pComb3X plasmid. 
VLs were growth in 0.5 L of super broth (SB) medium supplemented with 100 µg mL-1 
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ampicillin and 20 mM MgCl2 at 37 °C until OD600 of 0.9. Protein expression was induced 
with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and lasted for 16 h at 30 ºC. 
To evaluate VLs expression profile, 10 mL of each VL culture was recovered at different 
time points (0, 1, 2, 6 and 16 h). Bacterial pellets were harvested by centrifugation and 
resuspended in 20 mM NaH2PO4 pH 7.4, 500 mM NaCl and 20 mM imidazole for 
purification or PBS for western-blot supplemented with a protease inhibitors cocktail 
(Roche Diagnostics). Cells were lysed by sonication. Soluble protein was purified by 
immobilized metal ion affinity chromatography (IMAC) using HisTrap HP columns (GE 
Healthcare) coupled to an ӒKTAprime Plus protein purification system (GE Healthcare). 
E. coli Tuner (DE3) cells (Invitrogen, Thermo Fisher Scientific) were transformed 
with anti-HR1 VL construction plasmids. VLs were growth in 4 L of lysogeny broth (LB) 
medium at 37 °C until OD600 of 0.4. Protein production was induced with 0.2 mM IPTG 
and lasted for 4 h at the same temperature. The recombinant proteins were expressed as 
inclusion bodies to yield a sufficient amount of protein for downstream analysis. Bacterial 
pellets were collected and resuspended in 160 mL of 50 mM HEPES pH 8.0, 1 M NaCl, 
10 mM imidazole and 5 mM CaCl2 previous to disruption through sonication during 30 
min. The insoluble fraction was then resuspended in 80 mL of the same buffer and further 
disrupted by sonication during 20 min. The inclusion bodies were collected by 
centrifugation, resuspended in 40 mL of 50 mM HEPES pH 78.0, 1 M NaCl, 10 mM 
imidazole, 2 M urea and 5 mM CaCl2 and subjected to sonication to remove soluble 
contaminants. Finally, insoluble proteins were resupended in 25 mL of 50 mM HEPES 
pH 8.0, 1 M NaCl, 10 mM imidazole, 6 M urea, 1 mM 2-mercaptoethanol, 5 mM CaCl2 
and solubilized overnight at 4 °C with gentle agitation. Soluble denatured proteins were 
recovered after centrifugation and purified by IMAC, using His GraviTrap columns (GE 
Healthcare) according to manufacturer’s instructions.  
Purified VLs underwent buffer exchanging (refolding in case of anti-HR1 VLs) to 20 
mM HEPES pH 7.4, 0.1 M NaCl and 5% (v/v) glycerol using PD-10 Desalting Columns 
(GE Healthcare) according to manufacturer’s instructions. Purified VLs were kept at -80 
°C for long-term storage or at 4 °C for up to one month with no visible aggregation or 
loss of function. The protein yield was measured by Bradford method according to 
manufacturer’s instructions. Protein purity was as assessed by SDS-PAGE.  
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VLs expression and purification were analyzed by Western blot as described,350 where 
20 µg of bacterial extract or 500 ng of purified protein were loaded into 12%  Bis-Tris 
acrylamide gel. 
2.3.6 Inhibition assays 
HIV-1 laboratory-adapted strain NL4-3 (HIV-1NL4-3) production was performed 
as described354 and 50% tissue culture infectious dose (TCID50) determined as Borrego et 
al.343 HIV-2 and HIV-1 primary isolates from subtypes J and H were obtained from 
Borrego et al.343 HIV-1 variant NL4-3 D36G (parental) and HIV-1 variants resistant to 
T-20 NL4-3 (D36G) V38A/N42D and V38A/N42T (NIH AIDS Reagent Program) were 
propagated accordingly to Borrego et al.343 HIV-1 primary isolates from subtypes B and 
C were obtained from Calado et al.355 
For all the inhibition assays, viruses or HeLa243env/HeLa273Δenv cells were 
incubated with titrated amounts of the inhibitors during 1 h at 37 ºC prior to infection and 
HIV infectivity was measured 48 h postinfection. In Jurkat E6-1 (NIH AIDS Reagent 
Program) inhibition assay, HIV p24CA concentrations were measured by ELISA (NCI 
Frederick, MD, USA) according to manufacturer’s instructions. In inhibition assays with 
TZM-bl cells (NIH AIDS Reagent Program),343 luciferase or β-galactosidase expression 
was quantified with the One-Glow luciferase assay substrate reagent (Promega, USA) 
according to manufacturer’s instructions or as described in Da Silva et al,43 respectively. 
Cell-cell fusion assay was adapted from Schwartz et al.356 HeLa243env or HeLa273Δenv 
cells356 were co-cultured at a 1:1 ration with MAGI cells (NIH AIDS Reagent Program) 
in the presence of inhibitors. After 48 h, β-galactosidase expression was quantified as 
described.43 Peripheral blood mononuclear cells’ (PBMCs) isolation, maintenance and 
inhibition assays were performed as previously described355 with the following exception: 
at seven days postinfection, HIV p24CA concentrations were measured by ELISA (NCI 
Frederick, MD, USA).  The 50% inhibitory concentration (IC50) estimation and statistical 
analysis were performed as described.164,343 
2.3.7 Liposome preparation 
Large unilamellar vesicles (LUV) with controlled size and composition were 
prepared as described.357 Formulations composed of 1-palmitoyl-2-oleyl-sn-glycero-3-
phosphocholine (POPC; AvantiAvanti Polar Lipids; Alabaster, AL, USA) and a mixture 
of POPC and cholesterol (Chol; Sigma-Aldrich; St. Louis, MO, USA) in a 2:1 ratio were 
prepared. Each lipid formulation was first solubilized with spectroscopic grade 
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chloroform (Merck; Darmstadt, Germany) in a round bottom flask. A thin lipid film was 
formed after solvent evaporation under nitrogen flow and then in vacuum. Rehydration 
with 10 mM HEPES pH 7.4, 150 mM NaCl, 5% (v/v) glycerol and a series of 8-10 
freeze/thaw cycles yielded a multilamellar vesicle (MLV) suspension. This suspension 
was then extruded through a 100 nm pore polycarbonate membrane (Whatman/GE 
Healthcare; Kent, United Kingdom) using a LiposoFast-Basic plus Stabilizer setup 
(Avestin; Mannheim, Germany). The resulting LUV suspension was used in fluorescence 
spectroscopy experiments.  
2.3.8 Partition experiments 
A 15 mM LUV stock solution was successively added to 10 μM of either F63 or 
parental VL for final concentrations ranging from 0 to 5 mM. The sample was incubated 
for 10 min between each addition. The extent of sdAb partition was followed by steady 
state fluorescence emission performed in a Varian Cary Eclipse spectrofluorometer (Palo 
Alto, CA, USA). A 280 nm radiation wavelength was used to excite tryptophan (Trp) and 
tyrosine (Tyr) residues. sdAb emission profiles were collected in the range between 300 
and 450 nm. Fluorescence intensity was corrected for dilution, solvent background and 
light scattering.358 Partition constants (Kp) were determined by fitting the emission spectra 
integral (I) with the partition equation.359 
 
𝐼 =
𝐼W + 𝐾pγL[L]𝐼L
1 + 𝐾pγL[L]
 (1) 
In this equation, IW and IL are the emission spectra integral of the sdAb in the aqueous and 
lipid phase, respectively; γL is the lipid molar volume and [L] is the lipid concentration. 
2.3.9 Membrane dipole potential sensing 
LUV were pre-incubated with di-8-ANEPPS (Sigma-Aldrich; St. Louis, MO, 
USA) overnight with agitation, to ensure efficient probe incorporation into the lipid 
membrane. The final probe to lipid ratio was 1/50 (2 mol% di-8-ANEPPS relative to 
lipid). Assays were performed with final concentrations of 200 μM for LUV, 4 μM for 
di-8-ANEPPS and 9 μM for each sdAb, assayed separately. Variations in the membrane 
dipole potential were monitored by di-8-ANEPPS excitation spectra deviations. 
Experiments were performed in a Varian Cary Eclipse spectrofluorometer. Spectra were 
collected between 380 and 580 nm, with a fixed emission wavelength at 670 nm to avoid 
membrane fluidity artifacts.358 Excitation was corrected for solvent background noise. 
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Controls consisted in di-8-ANEPPS-stained LUV at the same final concentration but 
without the addition of the sdAb. These controls were used to obtain the differential 
excitation spectra. This was possible by subtraction of the normalized controls from 
normalized sample. The normalization was to the individual spectrum integral. 
2.3.10 Affinity measurements 
F63 binding kinetics was determined by surface plasmon resonance (SPR), using 
a BIAcore 2000 (BIAcore Inc.). Briefly, N36 was captured on a CM5 sensor chip (GE 
Healthcare) using amine coupling at ∼1000 resonance units. Serial dilutions of F63 were 
injected for 4 min and allowed to dissociate for 10 min before matrix regeneration using 
10 mM glycine pH 1.5. Signal from an injection passing over an uncoupled cell was 
subtracted from an immobilized cell signal to generate sensorgrams of the amount of F63 
bound as a function of time. The running buffer was used for all sample dilutions. 
BIAcore kinetic evaluation software (version 3.1) was used to determine KD from the 
association (Ka) and dissociation rates (Kd) using a one-to-one binding model. VLparental 
was used as negative control. 
 
2.4 Results 
2.4.1 Selection of anti-HIV VLs with elongated complementary-determining 
region 1 and complementary-determining region 3 
In contrast to regular binding regions, long and flexible CDR3 of camelid heavy-
chain antibodies25 can successfully target hidden and non-standard (immune-evasion) 
epitopes.31,344 We proposed to translate these CDR features to a non-camelid scaffold—a 
rabbit kappa VL domain 348 derived from a previously selected single-chain variable 
fragment (scFv).349 In addition to the stability already attributed to VL sdAbs,47,48,63,69 
their solubility seems less affected by sequence variation in CDRs than VH domains.47 
We chose a non-human domain due to the extensive CDR3 length heterogeneity naturally 
present in the kappa light-chains of rabbit antibodies, in contrast with human ones.360,361 
Furthermore, this particular VL domain was shown to be highly stable and soluble in the 
absence of its counterpart VH domain.348 The naturally longer and most exposed CDR of 
parental VL (CDR3; Fig. 2.1A), hereafter named VLparental, was grafted with a series of 
long CDRs containing a well-characterized paratope for hen egg-white lysozyme (HEL)30 
flanked by sequences of serines/glycines. These small amino acids—major contributors 
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to conformational flexibility of antibody CDRs79,362—were added to elongate the original 
CDR3 of 11 amino acids (aa) to 22, 26 or 30 aa (Fig. 2.1B).  
Evaluation of HEL targeting by each VL construction (VLCDR322, VLCDR326 
and VLCDR330) demonstrated that only VLCDR322 showed binding to HEL antigen 
(HEL binding was 0.86 ±0.06 for VLCDR322 vs 0.07 ±0.03 for VL; p<0.001; Fig. 2.1C). 
Longer CDR326 and CDR330 may have result in non-functional conformations of CDR3 
or the entire VL domain. The binding presented by the VLCDR322 was specific for HEL, 
not observed for BSA (Abs405 nm was 0.86 ±0.06 for HEL binding vs 0.06 ±0.04 for BSA 
binding; p<0.001; Fig. 2.1C). Additionally, VLCDR322 showed a dose-dependent binding 
to HEL (EC50 was 159.5 ±1.1 nM; Fig. 2.1D). We also performed a competitive ELISA 
by incubating VLCDR322 with soluble HEL (competitor), prior to immobilized-HEL 
binding, to better characterize this VL construction specificity. As expected, VLCDR322 
binding to immobilized-HEL decreased as the amount of HEL competitor increased (Fig. 
2.1D). No HEL binding was observed for VLparental. Besides VLCDR322 specificity 
towards HEL antigen, this result further proves VL capacity to bind soluble HEL in 
addition to immobilized-HEL. Finally, we analyzed VLCDR322 soluble expression in 
bacteria. Surprisingly, VLCDR322 showed higher soluble expression than VLparental for all 
tested post-induction time points (Fig. 2.1E). These results suggest that elongated-CDR 
sdAbs remain functional for antigen binding and could be more stable than standard VL 
domains.  
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Figure 2.1: Functional analysis of VLs with elongated CDR3. 
A) Three-dimensional structure prediction of VLparental by the I-TASSER protein structure homology-modelling server 
[11]. CDR1 is represented in red, CDR2 in yellow and CDR3 in blue. Framework is represented in grey. The molecular 
structure was represented using the UCSF chimera package 363. B) Schematic representation of VLs specific for hen 
egg-white lysozyme (HEL) with CDR3 of different sizes. HEL paratope is represented in grey at the central region of 
CDR3. Different serines/glycines sequences were added to the flanks of HEL paratope to increase the flexibility and 
size of the CDR to 22, 26 or 30 aa. The hexa-histidine tail (His6) was used for further purification of the VLs and HA 
tag for detection. C) Selection of functional anti-HEL VLs. Binding and specificity of each VL construction with 
distinct CDR3 sizes were evaluated by ELISA using HEL and BSA as antigens and the VLparental (VL) as negative 
control. VL domains were incubated with HEL or BSA-coated wells. Nonspecific binders were washed out. Bound VL 
domains were detected by HRP conjugated anti-HA antibody. Data are displayed as Abs measurement at 405 nm. Error 
bars correspond to standard deviation (n = 3; * p<0.05; *** p<0.001; **** p<0.0001; t-test). D) Binding analysis of 
VLCDR322 to HEL. (Left) Increasing concentrations of VLCDR322 and VLparental (VL) were incubated with HEL or 
BSA-coated wells. Data are displayed as Abs measurement at 405 nm. To facilitate data representation, HEL binding 
was calculated according to the following formula: AbsHEL-coated well-AbsBSA-coated well. Error bars correspond 
to standard deviation (n = 3) and n.a. to not applicable. (Right) Competitive ELISA. VLCDR322 and VLparental (VL) 
were pre-incubated with increasing quantities of soluble HEL (competitor HEL) at 37 ºC. After 1 h, this mixture was 
incubated with HEL-coated wells (immobilized-HEL). Data are displayed as percentage of immobilized-HEL binding 
(no competitor/immobilized-HEL = 100%) according to formula: [(Abscompetitor/immobilized-HEL-Abscompetitor/immobilized-
BSA)/(Absnocompetitor/immobilized-HEL-Absnocompetitor/immobilized-BSA)]*100. Error bars correspond to standard deviation (n = 3). 
E) Soluble expression of VLCDR322 in bacteria. The soluble expression yields of VLCDR322 and VLparental (VL) were 
compared by Western-Blot using the HRP conjugated anti-HA antibody for detection at five time points post-induction 
(t). 
 After validation of VLparental functionality in the presence of an elongated CDR3, 
we used it as a scaffold for synthetic library construction. This library was designed to 
select anti-HIV minimal antibody fragments with high-affinity towards a cryptic HR1 
region. We chose to elongate both CDR1 and CDR3 to increase theoretically the affinity 
of the selected sdAbs and at the same time avoid unspecific binding from the original 
CDR1. For the CDRs library construction, we used the previously validated strategy for 
HEL paratope grafting (Fig. 2.2A), restricted randomization of the central 12 aa with a 
degenerate codon (DVN) that only encodes for 12 of the canonical 20 aa. As most 
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encoded amino acids by DVN codon were described as abundant in natural CDRs and 
antigenic contacts 83, we expected to improve the selection of high-affinity sdAbs. 
Moreover, these amino acids seem to be sufficient to generate high-affinity and specific 
minimalist synthetic binders.83,362 A library of ~8.0x109 clones was generated, cloned and 
selected by phage display against a crucial-to-fusion, difficult-to-access and well 
conserved sequence on HR1 (HR1546–581(HXB2)), named N36
116 (Fig. 2.8 Supplementary 
Information). Apart from the cryptic nature of the entire HR1 region, N36 comprises 
residues of a particularly deep cavity, named hydrophobic pocket, described as highly 
conserved and a hot-spot for neutralization of HIV-1 infection 116,364. Despite the 
therapeutic interest, this pocket is particularly difficult to target in an infection context 
due to its extreme concave conformation. As shown in Fig. 2.2B, we isolated five VLs 
with strong binding to HR1 from the 329 clones screened by ELISA. A further 
characterization of HR1 binding showed a dose-dependent binding for all five selected 
VLs (Fig. 2.2C and Table 2.2 Supplementary Information). A competitive ELISA 
demonstrated that the five VLs showed a decreased binding to immobilized-HR1 as the 
soluble HR1 amount increased, confirming VLs specificity of recognition (Fig. 2.2C).  
 
Figure 2.2: Selection of anti-HIV VLs from the constructed synthetic library. 
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A) Schematic representation of VLs synthetic library. CDR1 and CDR3 were randomized in the central 12 amino acids 
(aa) represented by the X letter in grey. Serines/glycines sequence was added to the flanks to provide flexibility. The 
hexa-histidine tail (His6) was used for further purification of the VLs and HA tag for detection. B) Anti-HR1 VLs 
selection. The anti-HR1 VLs were expressed in bacteria and cell extracts incubated with N36 region of HR1 or BSA in 
ELISA plates. No VL represents cell extract with no VL expression. Nonspecific VLs were washed out. Bound VLs 
were detected by HRP-conjugated anti-HA antibody. The five phage-selected VLs out of 329 that presented highest 
binding values to HR1 are represented. Data are displayed as Abs measurement at 405 nm. To facilitate data 
representation, HR1 binding was calculated according to the following formula: AbsHR1-coated well-AbsBSA-coated well. C) 
HR1 binding analysis. (Left) Increasing concentrations of the purified five selected VLs and control VLparental (VL) 
were incubated with HR1 or BSA-coated wells. Data are displayed as Abs measurement at 405 nm. To facilitate data 
representation, HR1 binding was calculated according to the following formula: AbsHR1-coated well-AbsBSA-coated well. Error 
bars correspond to standard deviation (n = 3). (Right) Competitive ELISA. The five selected VLs and VLparental (VL) 
were pre-incubated with increasing quantities of soluble N36 region of HR1 at 37 ºC. After 1 h, this mixture was 
incubated with N36-coated wells (immobilized-HR1). Data are displayed as percentage of immobilized-HR1 binding 
(no competitor/immobilized-HR1 = 100%) according to formula: [(Abscompetitor/immobilized-HR1-Abscompetitor/immobilized-
BSA)/(Absnocompetitor/immobilized-HR1-Absnocompetitor/immobilized-BSA)]*100. Error bars correspond to standard deviation (n = 3). D) 
Selection of antiviral VLs. TZM-bl cells were infected with HIV-1NL4-3 laboratory-adapted strain in the anti-HR1 
VLs presence (C62, D103, F63, D104 and G54), after 3 h of inhibitors-viruses incubation. TZM-bl cell line expresses 
β-galactosidase and luciferase genes under control of HIV-1 promoter (LTR)—activated in the presence of HIV Tat 
protein (infection). VLparental (VL) represents the negative control. No VL represents cell extract with no VL expression. 
Data are displayed as percentage of infectivity inhibition (virus/no inhibitors = 0% inhibition; no virus/no inhibitors = 
background) according to the formula: [(Absvirus/inhibitors-Absbackground)/(Absvirus/noinhibitors-Absbackground)]*100. Error bars 
correspond to standard deviation (n = 2). E) Amino acid sequences of the five anti-HR1 VLs: C62, D103, F63, D104, 
G54 and control VLparental (VL). CDR1 is highlighted in red, CDR2 in yellow and CDR3 in blue. VLs backbone 
composed of four frameworks is represented in grey. 
To assess the antiviral activity of selected VLs, we performed a second screening 
(“functional screening”) against HIV-1NL4-3—encoding the G547D mutation responsible 
for less susceptibility to T-20 fusion inhibitor 162. From the five anti-HR1 VLs, F63 and 
D104 inhibited HIV-1NL4-3 infectivity by ~90% (Fig. 2.2D) and were selected for further 
characterization of antiviral activity. Except for CDR1 of VL D103 that was not 
randomized, DNA sequencing analysis confirmed that all CDR1 and CDR3 sequences of 
the five anti-HR1 VLs were unique (Fig. 2.2E). F63 and D104 VLs were expressed and 
purified in high yield and used for further functional characterization (Fig. 2.9 
Supplementary Information).  
2.4.2 Epitope mapping of antiviral VLs 
Epitopes of F63 and D104 were mapped by ELISA, using a set of 10 overlapping 
synthetic peptides covering the template HR1, and compared to the T-20 binding region 
(Fig. 2.3A). Both VLs exhibited similar target sequences within the central region of N36 
with short overlap at the C-terminus of T-20 binding region (Fig. 2.3B, C). F63 showed 
the strongest binding to peptide 5 (NH2-EAQQHMLQLTVWGIK-COOH), suggesting 
that it might contain its epitope (Fig. 2.3B). D104 showed similar binding to peptides 5 
and 6 (Fig. 2.3B), indicating that its epitope is located within the overlapping sequence 
of 11 aa NH2-HMLQLTVWGIK-COOH (Fig. 2.3A).  
DEVELOPMENT OF SYNTHETIC LIGHT-CHAIN ANTIBODIES 
AS NOVEL AND POTENT HIV FUSION INHIBITORS 
57 
 
 
Figure 2.3: Epitope mapping of antiviral VLs. 
A) Amino acid sequences of the 10 peptides (15-mer) representing the HR1 template (N36 in blue) used as antigens to 
map the F63 and D104 epitopes. Each peptide comprises 15 residues, 11 aa overlapping the subsequent peptide and an 
overhang of 4 aa at N-terminal region. B) Epitope mapping of F63 and D104 by ELISA, using 10 overlapping peptides 
of HR1 region and BSA as antigens and VLparental (VL) as negative control. Antiviral VLs were incubated with HR1 
peptides or BSA-coated wells. Only in the wells coated with epitope-containing HR1 peptides, VLs were detected with 
anti-HA-HRP antibody. In the remaining wells, VLs were washed out. Data are displayed as Abs measurement at 405 
nm. To facilitate data representation, HR1 binding was calculated according to the following formula: AbsHR1-coated 
well-AbsBSA-coated well. Error bars correspond to standard deviation (n = 3). C) Location of predicted F63 and D104 
epitopes in HR1 region. Amino acid residues in red constitute the T-20 origin and sequence. Amino acid residues 
highlighted in blue represent the N36 region. Dash lines represent HR1-HR2 interactions. 
2.4.3 Antiviral activity of VLs 
The antiviral activity of VLs was first compared with T-20 peptide against the 
HIV-1NL4-3. T-20 also binds HR1 impairing the virus-cell fusion driven by HR1-HR2 
interaction, an inhibition mechanism we reasoned to be similar to selected anti-HIV VLs. 
As shown in Fig. 2.4A, both F63 and D104 strongly inhibited HIV-1NL4-3 infection in 
TZM-bl cells (IC50 was 0.5 ±0.2 nM for F63 and 9.7 ±5.4 nM for D104). Remarkably, 
F63 was more active against HIV-1NL4-3 than D104 and T-20 (IC50 was 0.5 ±0.2 nM for 
F63 vs 9.7 ±5.4 nM for D104 and 3.1 ±1.9 nM for T-20). As expected, the VLparental did 
not inhibit HIV-1NL4-3. F63 and D104 also strongly inhibited HIV-1 infection similarly to 
T-20 in Jurkat cells (IC50 was 0.1 ±0.01 nM for F63, 0.6 ±0.1 nM for D104 and 0.1 ±0.01 
nM for T-20; Fig. 2.4B). No cytotoxicity was observed when either TZM-bl or Jurkat 
cells were incubated with the highest concentration of the VLs (Fig. 2.10 Supplementary 
Information). We also assessed F63 antiviral activity as a dimer. Surprisingly, F63 dimer 
did not inhibit HIV-1NL4-3 infection (data not shown), which is probably related to steric 
restrictions in F63 epitope access.  
We then asked whether F63 and D104 could inhibit cell-cell fusion between Env-
positive cells (HeLa243env) and adjacent CD4-expressing cells (MAGI) 356. Similarly to 
T-20 and in contrast to VLparental, F63 and D104 impaired HeLa cell-cell fusion in a 
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concentration-dependent manner (Fig. 2.4C). Fusion between control HeLa273Δenv—
without Env expression—and MAGI cells did not occur (data not shown). These results 
emphasize HIV-1 fusion as the target of F63 and D104. 
 
Figure 2.4: Antiviral activity of VLs. 
Percentage of viral infection inhibition was assessed against the laboratory-adapted strain HIV-1NL4-3 in TZM-bl (A) 
and Jurkat cells (B). Titrated amounts of VLs were incubated with HIV-1NL4-3 for 1 h at 37 ºC prior to infection. After 
48 h, HIV infectivity was evaluated by β-galactosidase activity measurement (TZM-bl) or p24CA quantification 
(Jurkat). Data are displayed as percentage of infectivity inhibition (virus/no inhibitors = 0% inhibition; no virus/no 
inhibitors = background) according to the formula: [1-(Absvirus/inhibitors-Absbackground)/(Absvirus/noinhibitors-
Absbackground)]*100. Error bars correspond to standard deviation (n = 3). C) Cell-cell fusion assay. HeLa cells presenting 
functional gp120/gp41 complexes at cell surface and expression of HIV-1 Tat protein (HeLa243env) were co-cultured 
during 48 h with CD4-expressing HeLa cells (MAGI) in the inhibitors presence. Prior to co-culturing, HeLa243env 
were incubated with titrated amounts of the VLs for 1 h at 37 ºC. MAGI cells have an integrated β-galactosidase gene 
under control of LTR promoter, similarly to TZM-bl cells. Fusion inhibition was assessed by β-galactosidase activity 
measurement. Data are displayed as percentage of fusion inhibition (HeLa243env cells/no inhibitors = 0%; no 
HeLa243env cells/no inhibitors = background) according to the formula: [1-(AbsHeLa243env/inhibitors-
Absbackground)/(AbsHeLa243env/noinhibitors-Absbackground)]*100. Error bars correspond to standard deviation (n = 3).  
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To test the hypothesis that F63 and D104 were as active as T-20 towards clinically 
relevant HIV isolates, the IC50 of VLs was evaluated against two HIV-1 and HIV-2 
primary isolates in TZM-bl cells. HIV-1 primary isolates belong to distinct subtypes of 
the major HIV-1 group M, clade J (93AOHDC250) 164 and clade H (93AOCA251) 164. 
HIV-2 primary isolates 03PTHCC12 and 10PTHSMNC 164 belong to the most prevalent 
HIV-2 group 365 (Group A, ~90% worldwide). Despite the divergent HR1 sequences of 
the HIV-1 primary isolates (Fig. 2.8 Supplementary Information), F63 neutralized both 
viruses (IC50 was 402 ±46 nM for 93AOHDC250 isolate and 469 ±41 nM for 
93AOCA251 isolate; Fig. 2.5A). Although F63 did not inhibit these HIV-1 primary 
isolates as potently as T-20, IC50 values are in the nanomolar range for both HIV-1 
subtypes (IC50 was 402 ±46 nM for F63 vs 1.3 ±0.4 nM for T-20 for 93AOHDC250 
isolate; 469 ±41 nM for F63 vs 0.4 ±0.1 nM for T-20 for 93AOCA251 isolate; Fig. 2.5A 
and Fig. 2.5B). This fact still supports F63 as a potent inhibitor of these two HIV-1 
primary isolates. In contrast to T-20, F63 also inhibited the two HIV-2 primary isolates 
in the nanomolar range (IC50 was 460 ±19 nM for F63 vs 2,855 ±483 nM for T-20 for 
03PTHCC12 isolate; IC50 was 433 ±38 nM for F63 vs 266 ±25 nM for T-20 for 
10PTHSMNC isolate; Fig. 2.5C and Fig. 2.5D). In contrast to F63, D104 did not inhibit 
either HIV-1 or HIV-2 primary isolates (data not shown). These results suggest that in 
addition to inhibition of HIV-1 non-B subtypes, F63 can be a potent inhibitor of HIV-2 
isolates. We also tested the antiviral potency of F63 in PBMCs against a panel of HIV-1 
primary isolates from the most prevalent subtypes B (developed countries) and C 
(developing countries). As shown in Table 2.3 Supplementary Information, the IC50 
values obtained for F63 were similar to T-20 in the nano-picomolar range. These results 
indicate that F63 also potently inhibits isolates from the most prevalent HIV-1 subtypes 
in primary lymphocytes, with comparable activity to T-20.  
Overall, F63 was as active as T-20 as judged by the IC50 against all tested HIV 
isolates (no significant p-value; Fig. 2.5E). Moreover, F63 was not significantly less 
active than T-20 either for HIV-1 or HIV-2 primary isolates (no significant p-value; data 
not show). These results indicate that F63 presents an antiviral activity similar to T-20.  
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Figure 2.5: Antiviral activity of VLs against HIV primary isolates. 
Antiviral activity of F63 was compared to the FDA-approved T-20 against HIV-1 (A and B) and HIV-2 (C and D) 
primary isolates. Titrated amounts of VLs were incubated with HIV primary isolates for 1 h at 37 ºC prior to TZM-bl 
cells infection. After 48 h, HIV infectivity was evaluated by luciferase activity measurement. Data are displayed as 
percentage of infectivity inhibition (virus/no inhibitors = 0%; no virus/no inhibitors = background) according to the 
formula: [1-(LUvirus/inhibitors-LUbackground)/(LUvirus/noinhibitors-LUbackground)]*100. Error bars correspond to standard 
deviation (n = 4). E) Mean IC50 values of F63 and T-20 for all tested HIV primary isolates (p<0.05; *** p<0.001; **** 
p<0.0001; n.s. = no significant; t-test). Bars represent median values.  
To test F63 neutralizing activity against HIV-1 strains resistant to T-20, we 
evaluated the susceptibility of two HIV-1 variants displaying well-defined mutations for 
T-20 resistance 162,366. HIV-1 variants resistant to T-20 derived from HIV-1 NL4-3 D36G 
(parental) susceptible to T-20 162,366. F63 presented no fold-increase of IC50 for all tested 
HIV-1 variants resistant to T-20 relative to parental HIV-1 (IC50 fold-increase was 0.66 
for NL4-3 (D36G) V38A/N42D; no significant p-value and 0.70 for NL4-3 (D36G) 
V38A/N42T; no significant p-value; Fig. 2.6). In contrast, T-20 IC50 was reported to 
present a fold-increase of approximately 3.94x103 and 1.61x104 for HIV-1 variants NL4-
3 (D36G) V38A/N42D and V38A/N42T, respectively, comparing to the parental HIV-1 
343. These data suggest that F63 could constitute an alternative in the treatment of patients 
infected with HIV-1 strains resistant to T-20.  
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Figure 2.6: Antiviral activity of F63 against HIV-1 strains resistant to T-20. 
Antiviral activity of F63 against HIV-1 variants resistant to T-20 NL4-3 (D36G) V38A/N42D (A) and V38A/N42T 
(B) was compared to HIV-1 variant susceptible to T-20 D36G (parental). Titrated amounts of F63 were incubated with 
HIV-1 variants for 1 h at 37 ºC prior to TZM-bl cells infection. After 48 h, HIV infectivity was evaluated by luciferase 
activity measurement. Data are displayed as percentage of infectivity inhibition (virus/no inhibitors = 0%; no virus/no 
inhibitors = background) according to the formula: [1-(LUvirus/inhibitors-LUbackground)/(LUvirus/noinhibitors-LUbackground)]*100. 
Error bars correspond to standard deviation (n = 2). Fold-increase represents fold-increase of IC50 relative to NL4-3 
D36G (parental). 
2.4.4 F63 interaction with lipid membranes 
Since T-20 antiviral mechanism is associated with membrane interaction, we also 
evaluated the lipid binding capacity of F63 against membrane model systems mimicking 
the major lipids of cellular membrane and cholesterol-rich viral envelope 367. In the 
presence of lipid membranes, variations in the fluorescent residue emission are typically 
associated with protein-membrane interactions 368. Taking advantage of the tryptophan 
residue (Trp; position 46 in F63 and 37 in VLparental Fig. 2.2E), we performed partition 
experiments based on the VL quantum yield variations. Fluorescence emission from F63 
Trp decreased with increasing lipid concentrations of the both membrane models tested 
(Fig. 2.7A, B). The Kp values retrieved from data fitting with the partition formalism were 
in the same order of magnitude for viral envelope and cell membrane models (Table 2.4 
Supplementary Information). The Kp correlates with the extent of protein interaction with 
the lipid membrane models—ratio between the concentration of a given molecule in two 
separate and immiscible phases. In contrast, we did not observe variations in the 
fluorescence emission of VLparental Trp (Fig. 2.7A, B). These results suggest that F63 
interact with lipid membranes, independently of the cholesterol content. Spectral 
properties of lipophilic probes such as di-8-ANEPPS, which are responsive to variations 
in membrane dipole potential, can also be exploited to study protein-membrane 
interactions 359. Excitation spectra of di-8-ANEPPS inserted in both membrane models 
underwent a red-shift to higher wavelengths—indication of a membrane dipole potential 
perturbation—only in the F63 presence (Fig. 2.7C, D). These observations complement 
the previous partition results and support the hypothesis that F63 has unique membrane-
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interacting properties, unlike VLparental. F63 also presented a binding affinity (KD) of ~8 
nM to N36 as determined by surface plasmon resonance (Table 2.5 Supplementary 
Information), establishing this VL as a high-affinity binder in the low-nanomolar range.  
 
Figure 2.7: F63 membrane interactions. 
Partition profiles of F63 and control VLparental (VL) towards 1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine 
(POPC; cellular membrane model) (A) and POPC:Cholesterol (2:1; virus envelope model) (B). 10 μM of F63 and 
VLparental were titrated with small volumes of LUV up to final lipid concentrations, [L]. sdAb intrinsic fluorescence 
emission, I, was collected for each [L], and normalized to the respective emission in the aqueous media, IW. The line 
represents the best fit of equation 1 to one of three independent replicates. Differential excitation spectra of di-8-
ANEPPS-labelled POPC (C) and POPC:Cholesterol (2:1) (D) liposomal membrane models in the presence of 9 μM of 
either F63 or control VLparental (VL). The respective amplitude is correlated with di-8-ANEPPS spectral shifts in 
response to membrane dipole potential perturbations. Graphs were obtained by subtraction of the normalized di-8-
ANEPPS excitation spectra controls from the spectra in the presence of each VL (normalization to the respective 
spectrum integral). The presented spectra constitute one of three independent replicates. 
 
2.5 Discussion 
HIV entry inhibition is a key component of any antiviral therapeutic scheme leading 
to impairment of de novo infection. In this chapter, we selected a broad and potent HIV 
fusion inhibitor from a synthetic repertoire of VL domains. Several studies have shown 
that VLs tend to aggregate less 47,48,63 and present higher antigen-binding properties 67,70 
than VH domains. In this study, we went further relative to others 68,369 and successfully 
selected a high-affinity VL with elongated CDRs. Our data suggest that the screening of 
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libraries containing CDRs-elongated antibody formats result in the selection of cryptic 
epitope binders, mimicking the longer and more flexible CDRs found in camelids 370. 
Here, we took advantage of VLs reduced size to target a sterically restricted region 
on HR1 of gp41 (N36). Together with the corresponding HR2 region, N36 is sufficient 
to form the 6HB structure responsible for the HIV fusion 116. Accordingly, a VL-N36 
interaction would prevent the 6HB assembly, leading to HIV entry impairment. Epitope 
mapping of the most potent HIV inhibitors revealed two similar sequences within the N36 
central region, previously described as part of a highly conserved cavity (hydrophobic 
pocket) essential for HR2 binding 116,120. Despite the location of D104 target region within 
the F63 target sequence, antiviral activity against HIV primary isolates was only observed 
with F63. Thus, our data seem to indicate that targeting of D104 epitope is insufficient 
for broad neutralization of HIV. Nevertheless, since D104 affinity was not determined we 
cannot exclude that it may influence viral inhibition. On the other hand, F63 epitope 
represents a promising target with ~60% conservation amongst HIV-1 subtypes and even 
HIV types (Fig. S2). This predicted epitope is also distinct from the T-20 binding region 
that has a low genetic barrier to drug resistance, mainly the Gly-Ile-Val sequence (HR136–-
38(HXB2)) 
162,371, as reinforced by the observed F63 inhibition of T-20 resistant HIV-1 
strains. Moreover, a substitution of a single residue on ~70% of the F63 predicted epitope 
would lead to impaired or non-functional HIV-1 entry mutants as reported by Sen et al. 
372 (Fig. S2). F63 epitope conservation and importance for HIV fusion together with the 
fact that this VL domain inhibited HIV-1 primary isolates from distinct subtypes similarly 
to T-20 and HIV-2 primary isolates highlight F63 potency and predict a high breadth for 
this inhibitor. Moreover, since T-20 has a limited activity on HIV-2 165,343 F63 could 
constitute an alternative to the treatment of this HIV type.  
The close proximity of gp41 to viral envelope and cellular membrane during HIV 
entry questions the role of membranes in gp41-targeting inhibitors mechanism. For 
example, T-20 shows considerable interaction with lipid membranes 346. Also, broadly 
neutralizing antibodies 2F5 and 4E10 are capable of stable epitope binding through cross-
reactive lipid interaction 373. We have assessed F63 membrane interactions through 
fluorescence spectroscopy methodologies and identified its partition towards lipid 
membrane models. Interestingly, the VLparental was unable to interact with these models, 
suggesting that this property was acquired during CDRs randomization and is associated 
to CDR1 and/or CDR3. From a pharmacological standpoint, membranes interaction is a 
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desirable property of an inhibitor mechanism 374, enabling the establishment of local and 
transient reservoirs both in the viral envelope and cellular membrane. Furthermore, the 
F63 lack of a Fc immune-triggering domain avoids cross-reactivity with lipids, a 
significant drawback in 2F5 and 4E10 application 375. 
To our knowledge, this is the first study presenting a synthetic VL sdAb designed 
as a potent inhibitor of HIV infection. Other fusion inhibitors with an antiviral activity 
similar to F63 were already described 168,376. However, F63 combine the reduced 
molecular weight of small non-antibody inhibitors with the specificity and high-affinity 
of antibody paratopes and the excellent biophysical properties and versatility of antibody 
formats. Despite VHH antibody fragments were also identified as anti-HIV inhibitors 
119,201,377–379, these variable domains target gp120 and were not synthetically randomized, 
being derived from llama immunization. Due to protease resistance and simplicity of 
sdAbs, F63 may also overcome major T-20 weaknesses such as oral administration 
preclusion, high production cost and short half-life 20,380. Additionally, F63 potency and 
biodistribution may be further improved by several strategies such as coupling of effector 
molecules (enzymes and cytotoxic drugs) and inhibitor-targeting to the cholesterol-rich 
areas where HIV preferentially enters 381, for example through attachment of cholesterol-
binding peptides. 
To address the expected immunogenicity of a rabbit VL, we successfully 
humanized F63 by removing residues potentially recognized as T-cell epitopes (des-
immunization) as described in Jones et al. 382. Humanized F63 neutralized HIV-1NL4-3 
laboratory-adapted strain similarly to rabbit F63 and proved to be more stable than its 
rabbit homolog due to alanine-substitution of unpaired cysteines performed along with 
F63 humanization (data not shown). It is conceivable that the rabbit-conserved cysteine 
at position 91—that forms an unusual disulfide bridge between variable and constant 
domains 383—together with the cysteine selected in CDR1 sequence were major 
contributors to the insolubility of F63 during the purification process. Therefore, our 
library design strategy could benefit from the replacement of DVN by the NDT 
degenerate codon, which encodes fewer cysteine residues and does not yield stop codons. 
In conclusion, we successfully developed a potent and broad fusion inhibitor of 
HIV-1 and HIV-2 infection using a VL sdAb as scaffold. We validated the selection of 
potent inhibitors based on a rational engineering strategy for synthetic library design. Our 
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findings also encourage exploration of CDRs elongation for the design or improvement 
of next-generation HIV inhibitors. 
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2.7 Accession codes 
The VL F63 sequence reported here has been deposited in the GenBank data base 
(accession number KT119563). 
DEVELOPMENT OF SYNTHETIC LIGHT-CHAIN ANTIBODIES 
AS NOVEL AND POTENT HIV FUSION INHIBITORS 
66 
 
 
2.8 Supplementary Information 
2.8.1 Supplementary Figures 
 
Figure 2.8:   HR1 peptide conservation across HIV-1 subtypes and HIV types and N36 importance for HIV-1 
entry. 
Amino acid sequence alignment of N36 from reference strains of the diverse HIV-1 subtypes (Top). Data based on 
2014 edition of the HIV Sequence Database (http://hiv-web.lanl.gov). Dashes indicate sequence identity to HIV-1 
consensus sequence of HXB2 strain from subtype B (first sequence). N36 sequence highlighted in blue corresponds to 
predicted F63 epitope. N36 underlined is D104 predicted epitope. Amino acid sequence alignment of N36 from HIV-
1 and HIV-2 types (Middle) 390. Dashes indicate sequence identity to HIV-1 consensus sequence. Importance of each 
individual amino acid of N36 for HIV-1 infection, according to Sen et al372 (Bottom). In the cited study, an alanine 
substitution was performed for each amino acid of N36 region, classifying each one according to the percentage of 
HIV-1 infection comparing to the wild-type. Wild-type mutants: >40% viral entry; Impaired entry-mutants: 5-40% 
viral entry and non-function entry mutants: <5% viral entry. 
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Figure 2.9: Analysis of purified VLs D104 and F63. 
Western-blot (A) and SDS-PAGE (B) of purified VLs D104 and F63. 
 
Figure 2.10: Viability assays. 
TZM-bl (A) and Jurkat cells (B) viability was determined in the presence of the highest used concentration of the 
inhibitors (F63, D104, T-20 and VL). Error bars correspond to standard deviation (n = 3).  
2.8.2 Supplementary Tables 
Table 2.1: PCR fragments and primers used in this study. 
VL CDR3 22 aa F 
> VL-F-SfiI 
5’- GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC -3’ 
> VL Framework 3 22 aa R 
5’-CCTCAATTCG TAGTAGCTA GCGTAGATG GTGGAGTCG GAGCCAC CGCCTGA 
ACAGTAGT AAGTGGCAGCATCGGC -3’ 
 
VL CDR3 22 aa R 
> VL CDR3 22 aa FF 
5’-GACT CCACCAT CTACGCT AGCTACTA CGAATTG AGGAGCG GAGGCG GAAGTT TTGC 
TTTCGGCGGAGGG-3’ 
> VL-R-SfiI 
5’-CCGCTCGA GCGGCTAAG AAGCGTAGTC CGGAACGTCG TACGGGTAAG AAGCGTAGTC 
CGGAACGTC-3’ 
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VL CDR3 26 aa F 
> VL-F-SfiI 
5’-GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3’ 
> VL Framework 3 26 aa R 
5’-CCTCAATTCGT AGTAGCTAGCG TAGATGGTGGA GTCGGAGCC ACCGCCAC CGCCTGAC 
CCGGAAC AGTAGT AAGTGGCAGCATCGGC-3’ 
 
VL CDR3 26 aa R 
> VL CDR3 26 aa FF 
5’-GACTC CACCATC TACGCTA GCTACT ACGAATT GAGGAG CGGAGG CGGAAG TGGT 
TCATTTG CTTTCGGCGGAGGG-3’ 
> VL-R-SfiI 
5’-CCGCTC GAGCGGCTAAG AAGCGTAGT CCGGAACGTCG TACGGGTAAG AAGCGTAGTCC 
GGAACGTC-3’ 
 
VL CDR3 30 aa F 
> VL-F-SfiI 
5’-GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3’ 
> VL Framework 3 30 aa R 
5’-CCTCAATTC GTAGTAGCTA GCGTAGAT GGTGGAGTCG GAGCCACCGCC AGAGCCTCCC 
CCGGAACAG TAGTAAGTGGCAGCATCGGC-3’ 
 
VL CDR3 30 aa R 
> VL CDR3 30 aa FF 
5’-GACTC CACCATC TACGCTA GCTACT ACGAATT GAGGAG CGGAGG CGGAAG TGGT 
TCATTTG CTTTCGGCGGAGGG-3’ 
> VL-R-SfiI 
5’-CCGCTCGA GCGGCTAAG AAGCGTAGTC CGGAACGTC GTACGGGT AAGAAGCG 
TAGTCCGG AACGTC-3’ 
 
HEL binders overlap 
> VL-F-SfiI 
5’-GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3’ 
> VL-R-SfiI 
5’-CCGCTCGAGCG GCTAAGA AGCGTAGTCC GGAACGTCGT ACGGGTAAG AAGCGTAGTCC 
GGAACGTC-3’ 
 
CDR1 randomization F 
> VL-F-SfiI 
5’-GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3’ 
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> CDR1-R 
5’-ACTTCCGCCTCCGCTGCAATTGATGGTGACTGTGCCC-3’ 
 
CDR1 randomization R 
> CDR1 library F  
5’-CAATTGCAGCGGAGG CGGAAGTD VNDVNDVNDVNDVNDVN DVNDVNDVNDVNDVN 
DVNAGCGGAGGCGGAAG TTGGTATCAGCAGAAACCAGGGC-3’ 
> VL-R-SfiI 
5’-CCGCTCGAG CGGCTAAG AAGCGTAGT CCGGAACGTC GTACGGGT AAGAAGCG TAGTCC 
GGAACGTC-3’ 
 
CDR1 randomization overlap 
> VL-F-SfiI 
5’-GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3’ 
> VL-R-SfiI 
5’-CCGCTCG AGCGGCTA AGAAGCGTAG TCCGGAACGTC GTACGGGTAA GAAGCGTAGTCC 
GGAACGTC-3’ 
 
CDR3 randomization F 
> VL-F-SfiI 
5’-GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3’ 
> CDR3-R 
5’-ACTTCCGCCTCCGCTACAGTAGTAAGTGGCAGCATCGGC-3’ 
 
CDR3 randomization R 
> CDR3 library F 
5’-CTTA CTACTGTAG CGGAGGCGGAAG TDVNDVNDVND VNDVNDVNDVN DVNDVNDVND 
VNDVNAGCGGAGGCGGAAGTTTTGCTTTCGGCGGAGGG-3’ 
> VL-R-SfiI 
5’-CCGCT CGAGCGGCTA AGAAGCGTAGTC CGGAACGTCGTAC GGGTAAGAAGCGTA 
GTCCGGAACGTC-3’ 
 
VL NheI/XhoI for pET28a (+) 
>VL-NheI-F 
5’- CTC GCT AGC GAG CTC GTG CTG ACC CAG-3’ 
> VL-XhoI-R 
5’-CCG CTC GAG GCT GCC TCC GCC TCC GCT TAG GAT CTC CAG CTC GGT CCC-3’ 
 
F63 monomer N-terminal 
>VL-NheI-F 
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5’- CTC GCT AGC GAG CTC GTG CTG ACC CAG-3’ 
>VL-NotI-R linker 
5’-TTTTCCTTTTGCGG CCGCTGCTACCTCCA CCTCCGCTGTGCTG GGCGGCCTGGCCA 
GGCCAGGCCGCCCA GCACAGCGG AGGTGGAGGTAGCAGCGGCCGCAAAAGGAAAA-3’ 
 
F63 monomer C-terminal 
>VL-NotI-F  
5’-AAG GAA AAA AGC GGC CGC GCC CAG GCG GCC GAG CTC-3’ 
> VL-XhoI-R 
5’-CCG CTC GAG GCT GCC TCC GCC TCC GCT TAG GAT CTC CAG CTC GGT CCC-3’ 
 
Table 2.2: Binding analysis of phage-selected VLs against N36. 
 EC50a ±SDb, nM 
C62 266.5 ±1.07 
D103 284.6 ±1.08 
F63 274.5 ±1.08 
D104 234.6 ±1.12 
G54 287.62 ±1.11 
VLc,d n.a. 
aEC50 (50% effective concentration) were inferred from sigmoidal dose-response (variable slope) curves. 
bSD stands for standard deviation of n = 3. 
cVL represents the VLparental. 
dn.a. stands for not applicable. 
 
Table 2.3: Antiviral activity of F63 against HIV-1 primary isolates in PBMCs. 
HIV-1 primary isolatea Subtyp
e 
F63 IC50b ±SDc, nM T-20 IC50b ±SDc, nM VLd,e 
UCFL1014 B 4.2 ±0.4 1.2 ±0.3 n.a. 
UCFL1025 B 0.4 ±0.1 0.2 ±0.1 n.a. 
UCFL1028 C 0.3 ±0.1 0.1 ±0.1 n.a. 
UCFL1029 B 7.0 ±2.0 2.5 ±0.8 n.a. 
aThe HIV-1 primary isolates were obtained from Calado et al 355. 
bIC50 (50% inhibitory concentration) were inferred from sigmoidal dose-response (variable slope) curves.  
cSD stands for standard deviation of n = 3. 
dVL represents the VLparental. 
en.a. stands for not applicable. 
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Table 2.4: Membrane partition constants of F63. 
 F63 Kp×103 ±SDa VLb Kp×103 ±SDa,c 
POPC 3.27 ±0.70 ~0 
POPC:Chol (2:1) 3.49 ±1.06 ~0 
aSD standard deviation of n = 3.  
bVL represents the VLparental.  
cData fitting was not possible. 
 
Table 2.5: Binding kinetics of F63. 
ka ±SDa, M
−1
s
−1
 kd ±SDa, s
−1
 KD = kd/ka ±SD
a, M K
D 
±SDa, nM 
6.1x10
4
 ±1.2 5.3x10
-4 
±0.3 8.8x10
-9
 ±1.1 8.8 ±1.1 
aSD standard deviation of n = 3 
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3.1 Abstract 
Small interfering RNAs (siRNA) application in therapy still faces a major challenge 
with the lack of an efficient and specific delivery system. Here, we present a novel 
strategy for sucessfully deliver of an anti-Human Immunodeficiency Virus (HIV) siRNA. 
Membrane translocation of RNAi effector was addressed by an engineered nanobody 
towards CXCR4 receptor, a major target expressed on HIV-susceptible T-lymphocytes. 
A validated siRNA molecule against HIV-1 gene tat was conjugated to fluorescein 
(FITC) and coupled to the CXCR4-specific nanobody through an anti-FITC single-chain 
variable fragment (4M5.3 scFv). We chose a high-affinity binder of FITC—4M5.3 
affinity constant in the fentomolar range—to minimize siRNA loss. The siRNA-fusion 
protein targeted CXCR4 positive cells, being detected at the surface and in the cytoplasm 
of a human T-lymphocytic cell line. Additionally, our construct silenced expression of 
luciferase reporter gene under control of Tat-driven HIV promoter and inhibited HIV-1 
infectivity. Similarly to RNA interference technology, zinc-finger transcription factors 
are potent modulators of gene expression. Accordingly, we further demonstrate the 
suitability of this nanobody as a vehicle for CXCR4 entry-dependent functionality of a 
delivered anti-HIV zinc-finger repressor. The present study demonstrates the potential of 
a specific delivery system for therapeutic HIV molecules based on nanobody chimeras 
towards CXCR4 receptor.  
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3.2 Introduction 
Methods of gene modulation have gained tremendous interest for therapeutic 
purposes. One of most well-known mechanisms is the RNA interference (RNAi). This 
technology of post-transcriptional gene silencing is mediated by RNA duplexes of 21-3 
nucleotides, termed small interfering RNAs (siRNAs), that trigger the cellular 
degradation of cognate mRNAs.224 RNAi silencing potency, specificity of target, 
universal conservation and broad application, namely to non-druggable targets, render it 
attractive for therapeutics. However, non-efficient cellular uptake of siRNAs, derived 
from their intrinsic negative charge and hydrophilicity, settles the need for delivery 
strategies that enable these RNA-based molecules translocation across cellular 
membrane. 
 Viral vectors and non-virus systems such as liposomal and polymeric nanocarriers, 
cell-penetrating peptides, ligands of cell receptors or antibody-based formats directed to 
cell-surface proteins are amongst the most widespread carriers of RNAi effectors.245,257,391 
Cell-targeted delivery presents several advantages such as reduction of required drug 
amount and prevention of off-target silencing and toxicity effects besides an overall 
potentiation of the therapeutic benefit. Nonetheless, and despite the diverse available 
methods, some limitations have been associated with systemic delivery of therapeutic 
siRNAs. For example, conjugation of these RNAi effectors with small size ligands such 
as aptamers or cell-penetrating peptides does not prolong short-term circulation due to 
threshold of renal excretion.279 Liposome-based methods are also known to easily trigger 
diverse inflammatory pathways261 and to hamper intracellular release of siRNA 
molecules.256 In other cases, a high dosage is required to induce a therapeutic benefit,236 
which results in burden costs, possible off-target effects and toxicity.  
Recent clinical trials reported tumor regression in patients treated with siRNA-
based drugs delivered by lipid carriers.392,393 Regardless of these advances, siRNA 
therapeutics in non-oncogenic diseases such as HIV infection remains a hurdle mainly 
due to lack of tumoral enhanced permeability and retention effect.394,395 Moreover, HIV-
target lymphocytes are not only described as hard-to-transfect cells with conventional 
lipid-based strategies but also as being concentrated on densely packed environments, 
limiting the size of the chosen carrier. HIV co-receptor CXCR4 is overexpressed in CD4+ 
T lymphocytes, main target cells of HIV, being efficiently internalized shortly after 
interaction with its natural ligand, SDF-1α.396 Previous studies have successfully 
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implemented a CXCR4-binding antibody for targeted delivery of cytotoxic drugs for 
cancer cells treatment397 as well as CXCR4-specific peptides for transfection of DNA 
molecules.398,399 Accordingly, we explored the potential of CXCR4 targeting to develop 
a novel strategy for antibody-based delivery of anti-HIV siRNAs.  
Here, we report the delivery of a siRNA targeting viral tat transcript via a scFv 
(single-chain variable fragment)-nanobody fusion protein, herein termed 4M5.3C. We 
show proof-of-concept of 4M5.3C capacity to provide selective binding and consequently 
internalization of siRNA cargo into CXCR4-bearing cells. Our results prove that 
4M5.3C-mediated delivery of siRNA silences HIV transactivator Tat expression and 
inhibits viral infectivity in cultured T-cells. We further demonstrate the use of this anti-
CXCR4 nanobody for targeted delivery of engineered zinc-finger repressors of HIV 
expression. In this approach, we show that zinc-finger inhibition activity is dependent on 
CXCR4-mediated endocytosis as delivery route. Both strategies support the concept of 
using nanobody-based constructions for targeted delivery of repressors of HIV 
expression. To the best of our knowledge, we demonstrate for the first time the potential 
of nanobody-based vehicles for efficient delivery of HIV inhibitor molecules.  
 
3.3 Materials and Methods 
3.3.1 Cells and viruses 
The following reagents were obtained through the NIH AIDS Reagent Program 
(Division of AIDS, NIAID, NIH): HeLa-tat-III from Drs. William Haseltine, Ernest 
Terwilliger and Joseph Sodroski,400,401 HeLa-Tat-III/LTR/d1EGFP from Dr. Satoh,402 
Jurkat Clone E6-1 T cells from A. Weiss,389 Sup-T1 from James Hoxie,403 TZM-bl from 
J. C. Kappes, X. Wu and Tranzyme Inc.,163,384–387 and pNL4-3 from M. Martin.
366 
HEK293T cells were purchased from ATCC.  
All cell cultures were maintained at 37 °C in a humidified atmosphere of 5% CO2. 
Jurkat and Sup-T1 cells were maintained in RPMI-1640 medium (Lonza) supplemented 
with 10% (v/v) fetal bovine serum (FBS; Thermo scientific), 1% (v/v) 
antibiotic/antimycotic solution (PSA; Thermo scientific) and 2 mM L-glutamine (Thermo 
scientific). HEK293T, HeLa-tat-III, HeLa-Tat-III/LTR/d1EGFP and TZM-bl were 
maintained in DMEM medium (Lonza) supplemented with 10% (v/v) FBS, 1% (v/v) PSA 
and 2 mM L-glutamine. In addition, HeLa-tat-III and HeLa-Tat-III/LTR/d1EGFP were 
kept in 1 mg/mL geneticin (Gibco). 
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3.3.2 siRNAs 
siRNA directed against tat was as previously described404: 
5’-GCGGAGACAGCGACGAAGAGCTTdTdT-3’ (sense);  
5’-GCUCUUCGUCGCUGUCUCCGCdTdT-3’ (anti-sense). 
The siRNA described was labeled with FITC at the 5’end of the sense strand (A4 
grade, Dharmacon Research). Scrambled siRNA (MISSION siRNA Universal Negative 
Control #1 6-FAM) was purchased from Sigma-Aldrich (Germany). 
3.3.3 Constructions 
FITC-binding scFv (4M5.3),405 CXCR4-targeting (282D2)406 and irrelevant 
nanobodies were synthetized by Geneart (Germany). Sequence of CXCR4-targeting 
282D2 nanobody was obtained from US 2011/0318347 A1 patent407 and sequence of 
KRAB-HLTR3333 from GenBank (Accession number AY518587.1). Fragments of 4M5.3 
scFv, KRAB-HLTR3 and CXCR4-specific and irrelevant nanobodies were originated by 
PCR using the primer sequences provided in Supporting Information (Table 3.1). 
4M5.3C, 4M5.3I, KRAB-HLTR3C and KRAB-HLTR3I constructions were assembled 
by ligation and cloned into the NheI and XhoI restriction sites of pET-21a(+) expression 
vector (Novagen). CXCR4-targeting nanobody and KRAB-HLTR3 alone were directly 
cloned into NheI/XhoI sites of pET-21a(+) plasmid. Constructions were verified by DNA 
sequencing analysis.  
3.3.4 Protein expression and purification 
Nanobodies for targeted siRNA delivery were produced by soluble protein 
purification in Escherichia coli shuffle cells (NEB). Chemically competent cells were 
transformed with 4M5.3C, 4M5.3I and anti-CXCR4 nanobody alone. Cultures were 
growth in 1 L of Super Broth (SB) medium supplemented with 100 µg/mL of ampicillin 
and 20 mM of MgCl2 at 30 °C until OD600 of 0.4, induced with 0.4 mM IPTG and further 
incubated at the same temperature for 4 h. Bacterial cells were collected and resuspended 
in 40 mL of 20 mM HEPES pH 7.4, 500 mM NaCl, and 20 mM imidazole before 
disruption through sonication during 20 min. Proteins were purified by IMAC, using His 
GraviTrap columns (GE Healthcare). Purified proteins were buffer exchanging to 20 mM 
HEPES pH 7.4, 500 mM NaCl and 5% glycerol using PD-10 Desalting Columns (GE 
Healthcare).  
Nanobodies for targeted zinc-finger delivery were produced by insoluble protein 
purification as previously described.408 Chemically competent E. coli BL21 (DE3) cells 
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(Stratagene) were transformed with constructions KRAB-HLTR3, KRAB-HLTR3C and 
KRAB-HLTR3I. Cultures were growth in lysogeny broth (LB) medium supplemented 
with 100 µg/mL of ampicillin at 37 °C until OD600 of 0.9, induced with 1 mM IPTG and 
further incubated at the same temperature for 4 h. Bacterial cells were collected and 
resuspended in 40 mL of 50 mM HEPES pH 8.0, 1 M NaCl, 10 mM imidazole, 2 M urea 
and 5 mM CaCl2 before disruption through sonication. The insoluble fraction was cleared 
by centrifugation, resuspended in the same buffer and further disrupted by sonication. 
Finally, insoluble proteins were resupended in 50 mM HEPES pH 8.0, 1 M NaCl, 10 mM 
imidazole, 6 M urea, 1 mM 2-mercaptoethanol, 5 mM CaCl2 and solubilized overnight at 
4 °C with gentle agitation. Soluble denatured proteins were recovered after centrifugation 
and purified by IMAC, using His GraviTrap columns (GE Healthcare). Purified proteins 
were renatured by buffer exchanging to 20 mM Tris-HCl pH 7.4, 1 mM MgCl2, 90 mM 
KCl and 0.1 mM ZnCl2 using PD-10 Desalting Columns (GE Healthcare).  
Purification of all proteins was confirmed by Western-blot technique as described 
previously.408 Purity was assessed by Coomassie-blue staining and quantification 
measured by Bradford method according to manufacturer instructions. 
3.3.5 Cell lines construction and virus production 
The protocol for construction of Jurkat CXCR4- cell line through CRISPR/Cas9 
gene knockout was adapted from Hou et al.409. For production of CXCR4-CRIPR/Cas9 
lentivirus, HEK293T seeded in 6-well plate were transfected with 1.3 µg lentiCXCR4-
gRNA-Cas9 #6, 1 µg psPAX2 and 0.7 µg pMD2.G plasmids (kindly provided by D. Guo) 
using lipofectamine 3000 reagent (Invitrogen) according to the improved lentiviral 
production protocol from the manufacturer. Jurkat T-cells (1.0x105) seeded in 24-well 
plate were transduced with 400 ng of p24 and incubated for 3 days. Receptor negative 
cells were sorted by flow cytometry, after negative selection of CXCR4-stained cells with 
APC (allophycocyanin) conjugated anti-human CXCR4 antibody 12G5 (Biolegend).  
To produce HIV viral particles, HEK293T seeded in 6-well plate were transfected 
with 3 µg pNL4-3 plasmid using lipofectamine 3000 reagent (Invitrogen) according to 
the improved lentiviral production protocol from the manufacturer.  
All viral titers were determined by HIV-1 p24CA antigen capture assay kit 
(Frederick National Laboratory for Cancer Research – AIDS and Cancer Virus Program). 
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3.3.6 Cell-surface binding and internalization of therapeutic siRNA 
FITC-conjugated scramble and tat siRNAs were mixed with 4M5.3C, 4M5.3I 
control or PBS at a molar ratio 2:1 (siRNA 200 pmol) in PBS for 1 h at 37 °C. CXCR4+ 
or CXCR4- Jurkat T-cells (2.0x105 in 100 µl culture medium) were treated for 2 h at 4 °C 
or 37 °C, washed twice with PBS or trypsin for 3 min, respectively, and analyzed by flow 
cytometry. For positive control, Jurkat cells were transfected with FITC-siRNA using 
interferin (Polyplus) according to manufacturers’ instructions. For competition assays, tat 
siRNA was mixed with 4M5.3C in the presence of crescent quantities of VHH α-CXCR4 
(competitor) for 2 h at 37 °C. Cells were washed twice with trypsin for 3 min and analyzed 
by flow cytometry for detection of FITC-positive population. 
3.3.7 Western-blot zinc-finger transcription factors 
Zinc-fingers detection in cells cytoplasm was adapted from Perdigão et al.410 
Briefly, ZF-TF proteins were diluted in RPMI medium containing 100 µM ZnCl2 and 
added to Jurkat cells (5.0x105) seeded in 6-well plate. Cells were treated for 2 h, 20 h and 
24 h. After treatment, cells were harvested and washed twice with trypsin for 3 min on 
ice to eliminate protein surface-binding. Cells were lysed with RIPA buffer (25 mM Tris-
HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% SDS) 
supplemented with EDTA-free Protease Inhibitor Cocktail Tablets (Roche, Basel, 
Switzerland) and TFs entry analyzed by SDS-PAGE. Samples were transferred onto a 0.2 
μm nitrocellulose membrane and detected with Immobilon Western Chemiluminescent 
HRP substrate (Millipore, Billerica, MA, USA) and Amersham HyperfilmECL (GE 
Healthcare, Little Chalfont, UK) chemiluminescence film. Zinc-finger repressors were 
detected by horseradish peroxidase-conjugated anti-HA monoclonal antibody (Roche, 
Basel, Switzerland). β-actin was used as an internal control and detected by a mouse anti-
β-actin monoclonal antibody (Sigma, St. Louis, MO, USA) and horseradish peroxidase-
conjugated goat anti-mouse IgG antibody (Bio-Rad, Hercules, CA, USA). 
3.3.8 Silencing/Shutdown of HIV LTR expression  
For siRNA-mediated LTR shutdown, TZM-bl cells were plated onto 24-well 
plates at a density of 1.0x105 cells per well. At 24 h after plating, cells were transfected 
with 500 ng of pTat plasmid (kindly provided by M. Simurda) using lipofectamine 3000 
(Invitrogen) according to manufacturer’s instructions. At 24 h post-transfection, scramble 
and tat siRNAs were mixed with 4M5.3C, 4M5.3I control or PBS at a molar ratio 2:1 
(siRNA 200 pmol) in PBS for 1 h at 37 °C.  TZM-bl cells were then washed with PBS 
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and treated with these siRNA carriers for 3 h. At 24 h post-treatment, luciferase activity 
was measured by OneGloTM Luciferase Assay System (Promega) according to 
manufacturer´s instructions. Luciferase activity was normalized to total amount of 
protein, as quantified by Bradford method. Cells’ viability was assessed by AlamarBlue 
reagent according to manufacturer’s instructions. 
For zinc-finger-mediated LTR shutdown, HeLa-Tat-III/LTR/d1EGFP cells were 
seeded into 24-well plates at 1.0x105 of confluence. After 24 h, cells were treated with 
200 nM of zinc-finger repressors and nanobody control for 3 h. Afterwards, cells were 
washed twice with PBS and analyzed by flow cytometry to evaluate GFP expression and 
exclude apoptotic cells after staining with Alexa 405-annexin V. 
3.3.9 HIV inhibition assays 
For siRNA-mediated viral inhibition, Sup-T1 cells (1.0x105) were infected with 10 
ng p24 of HIV-1 NL4-3 in 24-well plates. At 24 h post-infection, scramble and tat siRNAs 
were mixed with 4M5.3C, 4M5.3I control or PBS at a molar ratio 2:1 (siRNA 200 pmol) 
in PBS for 1 h at 37 °C and further incubated for with Sup-T1 cells 3 h. After 3 days of 
infection, HIV replication was assessed by p24 capsid quantification on culture 
supernatants (HIV-1 p24CA antigen capture assay kit; Frederick National Laboratory for 
Cancer Research – AIDS and Cancer Virus Program, Frederick, MD). 
 
3.4 Results 
3.4.1 CXCR4-targeted siRNA delivery by 4M5.3C 
We took advantage of a previously validated CXCR4-targeted heavy-chain 
variable domain from camelid (nanobody)406 and explored its potential to promote 
endocytosis-mediated delivery of a siRNA inhibitor. CXCR4-targeted nanobody, herein 
named NbCXCR4, was fused to the C-terminus of an anti-FITC scFv though the flexible 
linker GGGGS to originate the 4M5.3C chimera (Fig. 3.1A). The 4M5.3 scFv was chosen 
due to its exceptionally binding affinity for fluorescein (FITC)405 in the femtomolar range 
to carry the fluorochrome-conjugated siRNA. We also constructed a fusion protein 
composed of 4M5.3 portion and an irrelevant nanobody (non-targeting for mammalian 
cells) and the NbCXCR4 alone as negative controls for targeted delivery. All 
constructions were expressed and purified from E. coli, being purity assessed as >90% by 
SDS-PAGE (Fig. 3.1B). Proteins purification was also confirmed by Western-blot (data 
not shown).  
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Figure 3.1: Design of scFv-nanobody chimera for targeted delivery of FITC-conjugated siRNAs. 
A) Schematic representation of siRNA delivery constructs. Anti-FITC scFv (4M5.3) is positioned at the N-terminal of 
CXCR4-targeted (NbCXCR4) or irrelevant (Nb) nanobody to generate 4M5.3C or 4M5.3I, respectively. NbCXCR4 
control construct is devoid of anti-FITC scFv fragment. GGGS linkers were placed between the scFv fragment and the 
nanobody portion or histidine (His) and hemagglutinin A (HA) tags, respectively for protein purification or detection. 
B) SDS-PAGE analysis of purified protein constructs. Proteins were detected by Coomassie-blue staining. 
To evaluate receptor-specific internalization of siRNA, CXCR4+ or CXCR4- 
Jurkat T-cells were incubated with FITC-siRNA alone or in complex with 4M5.3C (2:1 
molar ratio). CXCR4-knockout cell line was constructed using the lentiCRISPR/Cas9 
technology for disruption of CXCR4 gene adapted from Hou et al409 (Fig. 3.2A). FITC-
siRNA lipid-based transfection of Jurkat T-cells was used as positive control for delivery. 
FITC fluorescence was only detected in CXCR4+ Jurkat T-cells incubated with 
4M5.3C+siRNA conjugate (Fig. 3.2B). As expected, FITC-labeled siRNA alone did not 
appreciably enter both cell lines. 4M5.3C-mediated internalization of CXCR4 appears to 
have no deleterious effect on cells viability. We observed that increase of FITC 
fluorescence in CXCR4+ Jurkat T-cells is dose-dependent of 4M5.3C+siRNA 
concentration (Fig. 3.2C). To further exclude a possible unspecific cell-permeability of 
4M5.3C, we compared FITC-siRNA binding (4ºC) and internalization (37ºC) between 
CXCR4-targeted 4M5.3C and irrelevant 4M5.3I control.  As showed in Fig 3.2D, only 
4M5.3C construct internalized the FITC-tagged siRNA into the CXCR4+ Jurkat T-cells 
(% FITC was 44.21 ±2.00 for 4M5.3C+siRNA vs 5.14 ±0.87 for 4M5.3I+siRNA; 
p<0.001). A similar effect was observed with CXCR4 binding at cell-surface, further 
verifying 4M5.3C specificity to CXCR4. To further evidence 4M5.3C specificity towards 
target receptor, we incubated CXCR4+ Jurkat T-cells with FITC-siRNA/4M5.3C 
complexes in the presence of NbCXCR4 alone as competitor for CXCR4 binding (Fig. 
3.2E). We observed that detection of FITC decreased as the concentration of NbCXCR4 
competitor increased, demonstrating that blocking CXCR4 receptor abolishes siRNA 
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internalization by 4M5.3C. Overall, these results indicate that engineered 4M5.3C can 
efficiently deliver FITC-conjugated siRNA through CXCR4-endocytosis. 
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Figure 3.2: CXCR4-targeted delivery of FITC-conjugated siRNA through scFv-nanobody chimera. 
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A) Histogram illustrating CXCR4 expression of CXCR4-positive or CXCR4-negative Jurkat T-cells stained with APC-
conjugated anti-CXCR4 and analyzed by flow cytometry. The solid black line represents the CXCR4+ Jurkat T-cells 
stained with anti-CXCR4 antibody. The dotted black line represents the CXCR4+ Jurkat T-cells unstained. The grey 
color represents the CXCR4- Jurkat T-cells stained with CXCR4-specific antibody. B) Histograms illustrating 
internalization of FITC-conjugated siRNA in CXCR4-positive or CXCR4-negative cells treated with 4M5.3C or siRNA 
alone, or 4M5.3C-siRNA complex (2:1 ratio) for 2 h at 37ºC. Cells were washed with trypsin to eliminate the CXCR4-
surface bound molecules before FITC detection by flow cytometry. “PBS” represents untreated cells. “Transfected 
siRNA” represents lipid-based siRNA transfection, the positive control for delivery. C) Percentage of FITC+ cells 
following flow cytometry analysis of CXCR4-positive Jurkat treated with increasing amounts of 4M5.3C-siRNA 
conjugation for 2 hours at 37ºC. D) Percentage of FITC+ cells following flow cytometry analysis of CXCR4-positive 
Jurkat treated with CXCR4-targeted 4M5.3C-siRNA of irrelevant 4M5.3I-siRNA conjugations for 2 h at 4 ºC (binding) 
or 37 ºC (internalization). Only cells incubated at 37 ºC were washed with trypsin. “PBS” represents untreated cells. 
“siRNA” indicates cells incubated with FITC-siRNA alone. E) Histogram illustrating FITC-siRNA internalization in 
CXCR4-positive Jurkat cells treated with 4M5.3C-siRNA in the absence (No competitor) or presence of increasing 
concentrations of NbCXCR4 competitor.  “PBS” represents the untreated cells. For panels a, b and e, histograms 
represent one of at least 3 independent assays. For panel c, values represent mean ± SEM of at least 6 independent 
assays. For panel d, values represent mean ± SEM of at least 10 independent assays. 4M5.3C+siRNA vs 
4M5.3I+siRNA ****p<0.0001 (Mann-Whitney test). 
3.4.2 4M5.3C-mediated siRNA delivery silences Tat-driven HIV transcription 
To evaluate whether 4M5.3C-delivered siRNA could silence target gene 
expression, CXCR4+ TZM-bl cells were transfected with pTat plasmid and afterwards 
incubated with 4M5.3C fusion protein carrying the tat siRNA. These cells encode the 
luciferase reporter gene under control of the long-terminal repeat (LTR)—HIV 
promoter—which in turn is transactivated by the Tat viral protein. Lipid-based 
transfection of tat siRNA was used as positive control for silencing of LTR expression. 
As demonstrated in Fig. 3.3A, siRNA delivered by 4M5.3C reduced LTR transcription 
by ~85% (p<0.05). In contrast, the presence of 4M5.3C+siRNA scramble (control) did 
not significantly affect luciferase transcription from the LTR promoter. We confirmed 
that 4M5.3C-mediated internalization of this non-targeting siRNA was similar to the anti-
tat siRNA (data not shown). Furthermore, silencing of LTR expression in the presence of 
4M5.3C+siRNA was not due to a loss in cell viability as demonstrated in Fig. 3.3B. These 
data indicate that delivery of anti-Tat siRNA through 4M5.3C construct specifically 
silences Tat-driven LTR transcription. 
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Figure 3.3: tat siRNA delivered by 4M5.3C silences Tat-driven LTR transcription in HIV reporter cells. 
A) Evaluation of Tat-driven LTR transcription assessed by luciferase activity in TZM-bl reporter cell line transfected 
with pTat plasmid followed by treatment with FITC-conjugated tat siRNA (siRNA), 4M5.3C alone or 4M5.3C-siRNA 
conjugation. Cells were transfected with pTat 24 hours previously to protein treatment. Cells were also incubated with 
FITC-tagged siRNA scramble conjugated with CXCR4-targeted 4M5.3C construct (4M5.3C+siRNA scramble) or 
irrelevant 4M5.3I control conjugated with tat siRNA (4M5.3I+siRNA). “Mock” represents untreated cells. 
“Transfected siRNA” represents lipid-based siRNA transfection for positive control of LTR transcription silencing. B) 
Viability of TZM-bl cells in presence of tat siRNA-conjugated 4M5.3C and 4M5.3I constructs. Cell viability was 
assessed by Alamar Blue viability assay 3 h after treatment. Values represent mean ± SEM of at least 3 independent 
assays and are normalized to pTat transfected cells. 4M5.3C+siRNA vs 4M5.3I+siRNA or vs 4M5.3C+siRNA 
scramble**p<0.01 (Mann-Whitney test). 
3.4.3 4M5.3C-mediated siRNA delivery inhibits HIV replication 
For the therapeutic siRNA to exert its antiviral activity, it is essential that 4M5.3C 
allows CXCR4-mediated internalization into HIV-infected cells. To evaluate inhibitory 
effect of CXCR4-targeted delivery of anti-Tat siRNA, a T-lymphotropic cell line was 
infected with HIV-1 laboratory-adapted strain NL4-3 (CXCR4-tropic) and afterwards 
incubated with 4M5.3C+siRNA conjugates. 4M5.3C loaded with tat siRNA reduced HIV 
replication on ~80% in T-lymphotropic cell line (Fig. 3.4A). We observed partial HIV 
inhibition with 4M5.3C alone, possibly due to NbCXCR4  reported viral neutralization 
activity as a fusion inhibitor.406 Nevertheless, HIV infection was dramatically decreased 
only when this construct was conjugated with anti-Tat siRNA. As demonstrated in Fig. 
3.4B, neither 4M5.3C conjugated with scramble siRNA nor tat siRNA conjugated with 
irrelevant 4M5.3I were able to inhibit NL4-3 infection. In conclusion, our results 
demonstrate that CXCR4-targeted delivery of anti-Tat siRNA by our 4M5.3C construct 
is able to directly inhibit HIV infection. 
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Figure 3.4: 4M5.3C-mediated delivery of tat siRNA inhibits HIV replication. 
A)  Percentage of HIV inhibition of T-lymphocytic SupT1 cell line infected with NL4-3 strain followed by treatment 
with 4M5.3C-siRNA anti-tat conjugation. After one day of NL4-3 infection, SupT1 cells were incubated in the presence 
of tat siRNA (siRNA) or 4M5.3C alone, or 4M5.3C+siRNA conjugation. “Mock” represents the non-infected cells. 
“HIV-1 NL4-3” represents infected cells with HIV-1 NL4-3 strain. “Transfected siRNA” represents lipid-based siRNA 
transfection for positive control of HIV inhibition.  B) Percentage of HIV inhibition of NL4-3 infected SupT1 cells 
treated with CXCR4-targeted 4M5.3C construct conjugated with tat siRNA (4M5.3C+siRNA scramble) or scramble 
siRNA (4M5.3C+siRNA scramble), or irrelevant 4M5.3I control conjugated with tat siRNA (4M5.3I+siRNA tat). HIV 
replication was measured by viral p24 capsid quantification 72 hours after treatment. Values represent mean ± SEM of 
2 independent assays with duplicates and are normalized to HIV-1 NL4-3. 4M5.3C+siRNA tat vs 4M5.3I+siRNA or 
vs 4M5.3C+siRNA scramble*p<0.05 (Mann-Whitney test). 
3.4.4 CXCR4-mediated endocytosis of engineered zinc-finger transcription factor 
for HIV repression 
To further explore NbCXCR4 capacity to potentiate delivery of HIV inhibitors, we 
developed an alternative to siRNA vehicle by directly fusing this variable domain with a 
zinc-finger transcription factor (ZF-TF) for HIV repression. Theoretically, any DNA 
sequence can be targeted by zinc-finger proteins that associated with functional domains 
such as transcription activator or repressors, are able to modulate gene expression. Even 
though zinc-binding domains were described as cell-penetrating proteins,323 the absence 
of a receptor-directed delivery system compromises the efficiency of these domains, 
increasing the dosage and potentiating off-target effects in non-relevant populations. 
Accordingly, we substituted the scFv portion of our delivery chimera by a ZF-TF 
(KRAB-HLTR3) towards the LTR HIV promoter, originating the KRAB-HLTR3C 
fusion protein (Fig. 3.5A). Among several ZF-TFs described to abrogate HIV 
replication332,333,336,337 KRAB-HLTR3 is one of the most potent presenting 100-fold HIV 
repression and target conservation among HIV-1 clades, mainly clade B333. HLTR3 
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constitutes the zinc-finger domain, whereas the KRAB is the transcriptional repressor 
moiety. Inhibitory capacity of KRAB-HLTR3 is related with affinity and chromatin-
accessibility of HLTR3 zinc-finger towards its target, repression potency of KRAB 
domain and the fact that HLTR3 binding-site overlaps the binding site of endogenous SP1 
transcription factors—required for HIV activation333. We also constructed a non-targeting 
control with nanobody irrelevant as targeting moiety, KRAB-HLTR3I (Fig. 3.5A). The 
two fusion proteins as well as the NbCXCR4 and KRAB-HLTR3 alone were purified 
from E. coli, being the purity confirmed by SDS-PAGE (Fig. 3.5B).  
We compared the entry efficiency between CXCR4-targeted KRAB-HLTR3 and 
zinc-finger repressor alone (KRAB-HLTR3) or in conjugation with the irrelevant 
nanobody (KRAB-HLR3I). Cellular extracts of CXCR4+ T-cells incubated with the 
diverse ZF-TF constructions were analyzed by Western-blot for detection of HA-tagged 
constructs. As shown in Fig. 3.5C, there are no apparent differences on ZF-TFs uptake 
among the distinct constructions. However, when receptor-mediated endocytosis occurs 
(KRAB-HLTR3C) the nanobody portion of the chimera alone is detected (~16 kDa) along 
with the entire nanobody-ZF-TF conjugation (~49 kDa). In contrast, when ZF-TF is taken 
up into cells through non-specific ZF cell-penetration, KRAB-HLTR3 and KRAB-
HLTR3I, only the whole zinc-finger repressor in fusion with irrelevant nanobody (~50 
kDa) or alone (~35 kDa) are detected by western-blot. We hypothesized that the linker 
region between the ZF-TF and nanobody portions is particularly vulnerable to the harsh 
conditions of endosomal environment, leading to the liberation of the zinc-finger 
repressor and nanobody molecules as individual entities into cell cytoplasm. The 
observed KRAB-HLTR3C chimera within cells may enter by non-specific ZF route 
instead of CXCR4 endocytosis. To evaluate functionality of CXCR4-endocyted ZF-TF, 
we assessed repression of HIV LTR promoter into CXCR4+ HeLaTat-III/LTR/d1EGFP 
cell line treated with KRAB-HLTR3C. This cell line encodes the HIV LTR promoter 
driving expression of a destabilized variant 1 of EGFP reporter (d1EGFP) and viral tat 
transactivator, which in turn causes a positive feedback on the LTR promoter to further 
enhance d1EGFP expression. Following protein treatment, cells were stained with 
labelled Alexa405-annexin V to exclude apoptotic cells and eliminate false LTR 
shutdown from non-viable cells. The KRAB-HLTR3 alone provided the positive control 
for repression of viral LTR promoter. Surprisingly, only the KRAB-HLTR3 in fusion 
with NbCXCR4 reduced d1EGFP fluorescence intensity of HeLa reporter line, indicating 
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ZF-TF mediated shutdown of LTR promoter (Fig. 3.5D). Non-targeting KRAB-HLTR3I 
control or NbCXCR4 alone had no effect on gene transcription from LTR promoter.  
Also, CXCR4 internalization due to nanobody-induced endocytosis has no negative effect 
on gene transcription from LTR promoter as demonstrated by the control of NbCXCR4 
alone. Our results demonstrate that KRAB-HLTR3C is able to target and silence HIV 
promoter in a targeted manner through CXCR4 endocytosis. 
 
Figure 3.5: Delivery of zinc-finger transcription factor for repression of HIV promoter through CXCR4-
targeting nanobody. 
A) Schematic representation of ZF-TF delivery constructs. KRAB-HLTR3 zinc-finger repressor is positioned at the N-
terminal of CXCR4-targeted (NbCXCR4) or irrelevant (Nb) nanobody to generate KRAB-HLTR3C or KRAB-
HLTR3I, respectively. NbCXCR4 control construct is devoid of HLTR3-KRAB repressor domain, while KRAB-
HLTR3 control is devoid of NbCXCR4 targeting domain. GGGS linkers were placed between the nanobody portion 
and the KRAB-HLTR3 domain or histidine (His) and hemagglutinin A (HA) tags, respectively for protein purification 
or detection. B) SDS-PAGE analysis of purified protein constructs. Proteins were detected by Coomassie-blue staining. 
C) Western blot of lysate of CXCR4+ Jurkat T-cells treated with KRAB-HLTR3 alone or in fusion with anti-CXCR4 
(KRAB-HLTR3C) or irrelevant nanobodies (KRAB-HLTR3I). After 3 h of protein treatment, cells were treated with 
trypsin to eliminate the surface-bound proteins and the extracts analyzed by western-blot. Proteins were detected by 
peroxidase-conjugated anti-HA tag antibody, using anti-β-actin for loading control. “PBS” indicates lysate from 
untreated cells. D) Percentage of normalized d1EGFP Mean Fluorescence Intensity (MFI) of HeLa-Tat-
III/LTR/d1EGFP treated with KRAB-HLTR3 or NbCXCR4 alone, or KRAB-HLTR3 in fusion with anti-CXCR4 
(KRAB-HLTR3C) or irrelevant nanobodies (KRAB-HLTR3I). “PBS” indicates untreated cells. Cells were analyzed 
by flow cytometry 3 h after protein treatment for detection of d1EGP. Flow cytometry analysis of d1EGFP expression 
was gated on live cells by excluding apoptotic cells stained with Alexa 405-annexin V. d1EGFP MFI is normalized to 
untreated PBS control gated on viable cells negative for Alexa 405. 
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3.5 Discussion 
Potency and breath of gene silencing methodologies hold promise for treatment of 
numerous diseases. Nevertheless, the lack of efficient and specific delivery methods 
continues to postpone the application of these technologies for human therapeutics. 
Despite its efficacy for treatment of solid tumors,411 delivery of therapeutic siRNAs 
in non-cancer applications is limited to disorders with simplified target-site accessibility 
such as ocular conditions or propensity to uptake/accumulate circulating molecules, as 
occurs with liver-located diseases.411,412 This is not the case for HIV infection. Despite 
remarkable advances in current antiretroviral therapy, HIV infection remains as a life-
threatening condition with serious morbidity effects. Accordingly, development of 
versatile HIV expression inhibitors such as RNAi,261 or additionally zinc-finger 
repressors,332,333,336,337 could provide a volte-face in this viral disorder therapeutics. 
However, inhibitors targeting HIV expression require a systemic delivery system due to 
the widespread distribution of virus-susceptible cells through human body.  
Here, we present targeted approaches to deliver inhibitors of HIV expression (siRNA 
and zinc-finger repressors) through engineered nanobody-based chimeras. Exceptional 
characteristics of nanobodies including high stability and solubility, low immunogenicity 
and increased tissue penetration25 make their a suitable option for targeting HIV-infected 
cells primarily located onto densely packed tissues. The absence of an effector region (Fc) 
in these antibody formats constitutes an additional safety feature to prevent undesirable 
immune activation. We developed a novel method for specific delivery of RNAi effectors, 
using a scFv-nanobody chimera (4M5.3C) for CXCR4-targeting of an anti-HIV siRNA. 
This chimera conjugates a validated nanobody 238D2406 responsible for membrane 
translocation through CXCR4-mediated endocytosis with the 4M5.3 antibody fragment, 
a scFv with exquisitely binding affinity towards FITC fluorochrome405 for promoting 
efficient uptake of FITC-conjugated siRNA effectors. 
In this study, we demonstrate 4M5.3C-mediated delivery of anti-tat siRNA to 
CXCR4-bearing cells, abolishing transcription from HIV LTR promoter. These data 
confirm the specificity of our delivery strategy towards CXCR4+ cells and ensures the 
silencing functionality of the delivered therapeutic siRNA. Delivery of 4M5.3C+siRNA 
conjugates also impaired viral replication in a T-lymphocytic cell line. Overall, these 
results validate the reported 4M5.3C chimera as a vehicle for delivery of anti-HIV 
siRNAs further demonstrating the potential of ligand-dependent CXCR4 endocytosis as 
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an entry route for therapeutic molecules as others already described.397–399,413 Few others 
reported targeted delivery of anti-HIV siRNAs, specially through antibody-based 
vehicles.261 Moreover, none described a nanobody format as targeting moiety.250,251,414  
In this chapter, we also fused a zinc-finger repressor to the NbCXCR4 (KRAB-
HLTR3C) for further testing a strategy of endocytosis-dependent functionality. Zinc-
finger domains have an intrinsic cell permeability,323 which surpasses the need for a 
delivery system. However, ZFPs lack of specificity leads to an inefficient therapeutic 
scheme and indesirable off-target effects. Opposed to non-targeted irrelevant chimera 
(4M5.3I), we detected the NbCXCR4 portion disproved of HLTR3-KRAB repressor into 
the intracellular environment, which indicates chimera hydrolysis between the nanobody 
and transcription factor portions in consequence of endocytosis delivery. On the other 
hand, only the CXCR4-targeted KRAB-HLTR3 exhibited repression of gene expression 
from HIV LTR promoter. These data seem to indicate that targeted-receptor endocytosis 
is required to assure zinc-finger repressor release and access to the cellular nucleus to 
perform gene modulation. Moreover, we did not observe any significant cytotoxicity 
associated with our chimera treatment. We believe that this should be related with the low 
range of protein concentration (not surpassing 0.2 µM) required for therapeutic benefit, 
derived from the increased potency of our strategy for enhanced ZF-TF delivery mediated 
by CXCR4-endocytosis. Previously, Meiler and co-workers already described a ligand-
mediated delivery of ZFPs through transferrin receptor for ZF-based nucleases,415 
demonstrating that endocytosis-mediated delivery enhanced ZF cell-penetration and 
consequently its activity. Other study had also reported successfully delivery of zinc-
finger repressors, although through a non-specific system of protein transduction 
domain.416 Overall, these results support the potential of targeted delivery of KRAB-
HLTR3 repressor to inhibit HIV replication. Further studies have now to be performed to 
confirm this hypothesis such as prove of KRAB-HLTR3 presence on the nucleus only 
when delivered through CXCR4 endocytosis. 
We anticipate that our strategy for CXCR4-targeted delivery of siRNA or zinc-finger 
inhibitors will provide broad inhibition of HIV replication apart from its tropism, as all  
infected cells possess this coreceptor.417,418 The usage of a cellular receptor for targeted 
delivery also constitutes an advantage of our strategy relative to others,248,250,419 since 
viral targets are prone to mutational modifications and limit therapeutic effect to already 
infected and actively replicating (non-latent) cells. Also, we cannot exclude the 
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possibility of using this system as a dual-inhibitory approach for CXCR4-tropic virus, as 
nanobody portion of our chimera was previously validated as a fusion inhibitor of HIV 
infection through binding competition with viral co-receptor CXCR4.406  
In conclusion, the presented study provides a new paradigm for delivery of HIV 
repressor molecules by CXCR4-targeted nanobody. Moreover, we expect that this 
method could pave the way for novel delivery systems of HIV inhibitors.  
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3.7 Supplementary Information 
3.7.1 Supplementary Tables  
Table 3.1: PCR fragments and primers used in this study. 
scFv 4M5.3C αFITC for chimera construction 
>scFv4M5.3-αFITC-F-NheI  
5’ – GCACCACT AGCTAGCTACCCCT ACGACGTGCCTGATT ACGCCGGAGGAT CCGGAGGA -
3’ 
>scFv4M5.3-αFITC-R-SacI  
5’ -AGTCTGGGTCAG CAGGAGCTCGCT TCCGCCTCCTCCGCT CACTGTCAC-3’ 
 
Nanobody 282D2 αCXCR4/Nanobody irrelevant for chimera construction 
> Nanobody-F-SacI 
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5’-CGAGCT CGAGGTGC AGCTGG TGGA-3’ 
> Nanobody-R-XhoI 
5’- CCGCTCGAGT CATGCGTAATC AGGCACGTCGTA GGGGTACGATCC ATGGTGATG 
GTGATGGTGATG GTGGCTGCCTCCGC CTCCACTGCTGCTCAC GGTCACCTG -3’ 
 
Nanobody 282D2 αCXCR4 alone 
> Nanobody-F-NheI 
5’-CTAGCT AGCGAGGTGC AGCTGGTGGA-3’ 
> Nanobody-R-XhoI 
5’- CCGCT CGAGTCATGCGT AATCAGGCACGTCGTA GGGGTACGAT CCATGG 
TGATGGTGATG GTGATGGTGGCT GCCTCCGCCTCC ACTGCTGCTCA CGGTCACCTG -3’ 
 
KRAB-HLTR3 for chimera construction 
> KRAB-HLTR3-F-NheI 
5’- GGAATTCCATATGGATGCTAAGTCACTGACTGCCT -3’ 
> KRAB-HLTR3-R-SacI 
5’- CGAGCTCGCTTCCGCCTCCGCTACTAGTTTTTTTACC -3’ 
 
KRAB-HLTR3 alone 
> KRAB-HLTR3-F-NheI 
5’- GGAATTCCATATGGATGCTAAGTCACTGACTGCCT -3’ 
> KRAB-HLTR3-R-XhoI 
5’- CCGCTCGAGTCAT GCGTAATCA GGCACG TCGTAGGGG TACGATCC ATGGTGATGG 
TGATGGTGATG GTGGCTGCCTCCGCCTC CGCTACTAGTTTTTTTACC -3’ 
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Recent advances on antibody engineering towards novel scaffolds and formats 
have paved the way for an innovative and promising class of biotherapeutic molecules. 
The antigen-binding sites of single-domain antibody (sdAb) fragments are particularly 
suitable to be tailored to create high affinity and specific binders. On the other hand, the 
peculiar heavy-chain only antibodies from camels allows to isolate autonomous variable 
domains (nanobodies) with favorable physical characteristics and exquisite binding 
capacity towards non-standard epitopes. 
Despite progresses on cART development and implementation, HIV infection 
continues to be a major worldwide hurdle due to disease persistence, viral resistance, and 
complications/toxicity of standard therapy. The exploration of innovative therapeutic 
approaches together with the increasing knowledge on virus pathogenesis could bring a 
new era of antiretroviral molecules for control of this lifetime disease. Accordingly, 
promising classes of HIV inhibitors are now beginning to be explored for clinical 
purposes such as antibody-, RNAi- and ZF-based molecules (aidsinfo.nih.gov). However, 
the lack of efficient and specific delivery systems could constitute a serious drawback on 
the implementation of these effector molecules for human therapy as antiviral drugs. 
Overall, there is urgent need to design and engineer more potent and broad therapeutic 
approaches for HIV infection as well as the platforms to their efficient and specific 
delivery. 
The present thesis set out to explore the potential of engineered sdAbs for 
treatment of HIV/AIDS condition, either as broad and potent inhibitors of HIV infection 
or as vehicles for targeted antiretroviral delivery. 
In Chapter I, we presented a general introduction to the antibody engineering field, 
in particular single-domain antibodies characteristics and state-of-the-art in therapeutic 
applications as well as synthetic libraries tailoring. We also introduced HIV virus biology 
and therapeutics with focus on unmet needs and drawbacks of available treatment scheme. 
In Chapter II, we have explored a strategy for the design of synthetic enlarged 
CDRs to develop a sdAb inhibitor of HIV infection. For this purpose, we took advantage 
of a previously validated rabbit scaffold to construct a library of light-chain antibodies 
(VL domains) with combinatorial restriction bias natural present residues at antigenic 
sites. This approach pretended to assure library’s quality through high percentage of 
functional clones and intended high-affinity binders. VL fragments were selected by 
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phage display technology for direct binding to the crucial-to-fusion and conserved N36 
region on viral envelope glycoprotein. The improved penetrability of sdAbs fragments 
make them more suitable to target sterically occluded cavities than alternative formats 
such as Fabs and scFvs. Because of extremely convex nature of N36 region, we designed 
sdAbs harboring long and flexible CDRs to further improve target accessibility by these 
fragments.119,420–422 We narrowed five potential HIV inhibitors with specific binding to 
N36 peptide to one VL showing broad HIV neutralization, herein named F63. The 
potency and breath activity of F63, evidenced through the proved neutralization of 
distinct HIV-1 and HIV-2 strains, also confirms the conservation and importance of N36 
region for virus infection as well as rationalize its immune evasion nature. On the other 
hand, the verified F63 propensity for lipid membranes interaction is shared with other 
potent entry inhibitors of HIV infection.346,347 Nonetheless, further evaluation of in vivo 
efficacy/safety of F63 is required.  
Our data seem to validate the selection of long CDRs bias cleft epitopes, 
evidencing the successfully translation of protuberating nature from camel and shark 
CDRs into alternative scaffolds. Additionally, our results reveal good perspectives for the 
screening of this synthetic library against alternative non-standard (cryptic) targets such 
as active sites of enzymes. Accordingly, this repertoire applicability could be 
exponentially expanded towards therapeutics of other disorder types or 
diagnostic/investigational approaches. The applicability of this dAb does not also have to 
be limited to neutralization of cell-free virus and inhibition of cell-cell HIV transmission. 
This fusion inhibitor can be further tested as microbicide or PrEP (pre-exposure 
prophylaxis) drug for prevention of HIV acquisition. Also, it would be interesting to 
evaluate dAb capacity to deliver toxic payloads to HIV-bearing cells, setting this minimal 
antibody fragment with a dual-antiviral activity, rare in HIV inhibitors. This potential is 
supported by previous studies describing antibodies targeting epitopes on gp41 HR loops 
as the most effective immunotoxins (antibody-toxin conjugations).423,424 In resume, the 
data presented in Chapter II evidence the essential role of CDRs engineering, either in 
diversity or length, for the successfully design of synthetic libraries, amenable to be 
screened against therapeutically relevant and difficult-to-access targets such as cryptic 
N36 region on HIV surface glycoprotein. Additionally, these results provide proof-of-
principle that engineered rabbit domain antibodies exhibit remarkable efficiency and 
cross-reacting neutralization of HIV-1 and HIV-2 infection, establishing a novel class of 
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potent viral inhibitors based on light-chain sdAbs. These domains can also help to identify 
original conserved epitopes as well as elucidate the virus mechanisms of entry and 
evasion from immune system. 
In Chapter III, we developed a strategy for specific delivery of novel classes of 
HIV inhibitors, in this case repressors of viral gene expression. We took advantage of a 
previously validated nanobody towards CXCR4 receptor to engineer a fusion 
construction for targeted delivery of an anti-HIV small interfering RNA (siRNA). This 
strategy is based on the design of a nanobody targeting domain fused with an anti-FITC 
scFv fragment to carry FITC-conjugated siRNA. The nanobody-based chimera (4M5.3C) 
delivered the anti-tat siRNA specifically to CXCR4+ cells, being the functionality of the 
delivered RNAi inhibitor proved through silencing of gene transcription from Tat-driven 
virus promoter and prevention of HIV-1 replication. In addition, we constructed a chimera 
for targeted delivery of an engineered zinc-finger repressor of HIV (KRAB-HLTR3C) 
through CXCR4 endocytosis. Incorporation of a nanobody fused to zinc-finger repressor 
turned its activity dependent of endocytosis-mediated entry, with nanobody-fused zinc-
finger chimera presenting shutdown of HIV LTR promoter only when targeted to CXCR4 
receptor. Our results indicate the release of zinc-finger repressor from nanobody chimera, 
probably in consequence of endosomal harsh conditions following CXCR4-endocytosis, 
and a tendency for the hydrolysis of the linker sequence between the zinc-finger repressor 
and the nanobody portions.  
The results from this Chapter validate sdAbs applicability for specific delivery of 
antiviral inhibitors, evidencing the efficacy of the targeted molecules as repressors of HIV 
gene expression. Despite the reported positive results, in vivo studies must validate this 
nanobody-based strategy for systemic delivery of anti-HIV siRNAs and zinc-finger 
repressors through CXCR4-mediated endocytosis. Furthermore, this strategy may present 
bias towards virus-infected cells. This phenomenon is supported by HIV requirement and 
perpetuation in activated T-cells, where CXCR4 expression is up-regulated.425 It would 
be interesting to evaluate capacity of scFv-nanobody construct to provide a shield against 
serum nucleases-mediated degradation of siRNA although chemical modifications on 
carried siRNA may also provide the same effect.261 The ability of scFv-nanobody chimera 
to mask therapeutic siRNA from immune system would be also of value to explore. 
Extension of siRNA half-life should be confirmed by pharmacokinetics studies though 
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the size of the 4M5.3C+siRNA complex is estimated in ~52 kDa, well above the renal 
filtration cut-off (30 kDa). Both delivery strategies can also be tested against latently 
infected cells. Impairment of provirus (integrated HIV genome) activation is not only 
important to avoid virus spread as assumes a crucial role on “lock out” strategies for latent 
infection inactivation.426 In these approaches, the full suppression of HIV provirus into a 
deep dormant status is expected to conduct to the natural elimination of HIV latent cells 
through cells renewal process. Our data anticipate a broad applicability of this strategy 
towards non-HIV diseases and within alternative therapeutic molecules. Alternative 
nanobody portions may modify delivery specificity of the chimera, as scFv fragment 
could also be replaced by RNA-binding molecules. Moreover, the possibility to multiplex 
siRNA molecules against diverse targets could enable therapeutically managing of 
distinct diseases within a single individual. For example, CXCR4 is an overexpressed 
receptor on malignant cells, constituting an attractive target for treatment of cancer 
diseases406 such as AIDS-related lymphoma—common secondary condition of HIV-
infected patients. Alternative zinc-finger effectors,292 including site-directed nucleases, 
recombinases or transcription activators, are as well expected to be delivered by this 
strategy. In resume, these two strategies for HIV inhibitors delivery pretend to further 
demonstrate the potential of minimal antibody fragments for therapeutic purposes as 
component vehicles of antiretroviral effectors. 
In conclusion, the present thesis provides proof-of-concept on single-domain 
antibodies usefulness in distinct therapeutic approaches for AIDS epidemic. We 
demonstrate the potential of rational design in tailoring a fit-to-purpose antibody 
fragment, in this case a broad fusion inhibitor of HIV infection based on a VL domain 
from rabbit-origin. On the other hand, we explored a nanobody-based platform for 
targeted delivery of distinctive technologies for HIV expression downregulation, either 
through zinc-finger transcriptional repressors or siRNA gene silencers. Accordingly, our 
study give insights into the engineering of highly attractive minimal domains for antiviral 
therapeutics, providing the basis for development of next-generation sdAbs for 
HIV/AIDS treatment. 
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